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The field of radiation oncology (RO) involves the use of highly advanced 
techniques to treat cancer and safely spare healthy organs. The discipline has 
experienced rapid growth in the past 25 years, with technological advancement as 
the driving force. Available data and an instrument to effectively measure the 
accessibility of innovation in the field were lacking. The purpose of this study was 
to investigate the accessibility of innovative services in RO in the United States 
and assess possible diffusion patterns. Two hundred and forty medical physicists 
practicing in RO in the United States completed a custom Internet-based survey. 
The diffusion of innovation theory was used as the theoretical framework for the 
study. A quantitative cross-sectional analysis was performed to assess how 
innovation scores may vary depending on individual and organizational factors. 
ANOVA, Spearman correlation, and multiple linear regression were used to 
analyze the data. University affiliation, urbanicity, appreciation, and motivation 
were found to be statistically significant factors affecting accessibility to 
innovative services. Statistically significant barriers preventing innovation were 
lack of evidence, increased complexity, staffing constraints, lack of interest from 
others, lack of interoperability, and lack of reimbursement. Medical physicists are 
in a leadership position to influence the adoption of innovative services in RO. 
Encouraging the utilization of innovative and Food and Drug Administration-
approved techniques may improve cancer outcomes and consequently have a 
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Chapter 1: Introduction to the Study 
Introduction 
The field of radiation oncology (RO) involves using high-energy radiation 
to target cancer lesions while sparing the surrounding healthy tissues (American 
Cancer Society, 2018). The field experienced rapid growth in the early 2000s, 
with the development of innovative techniques, such as intensity-modulated 
radiation therapy (IMRT). This technique allowed clinicians to “bend” radiation 
and customize each patient treatment by creating concave dose distributions that 
spare healthy tissues (Chen, 2014). This rapid growth paved the way for an array 
of other innovative techniques, such as advances in imaging and oncology 
informatics (Chetty et al., 2015). 
Many fields in health care struggle to implement innovative techniques 
such as these in the clinical workflow. The adaptation of innovation within 
discrete organizations is well understood, yet how the entire health care system 
transforms to accept health care innovations and thus improve population health is 
abstruse (Parston et al., 2015). Morris, Wooding, and Grant (2011) estimated that 
it takes 17 years for an innovation to spread throughout the health care industry. 
This time lag is more prominent in low-resource settings, leading to inequalities 
(Keown et al., 2014). In RO, differences in treatment modalities have a notable 
impact on cancer survival, yet centers offering innovative treatment techniques 




Jacobs et al. (2016) investigated the innovations adopted in Dutch RO 
centers. The authors found that in the Netherlands, RO centers implement on 
average 12 innovations per year. In reviewing the literature, there are no current 
studies quantifying the diffusion of innovation in RO across the United States. 
The purpose of this study was to fill this gap in the literature. University 
affiliation and urbanicity were investigated as possible predictors. The role of 
medical physicists was also investigated by using an array of demographic 
parameters and context-specific antecedents to develop a predictive model for 
accessibility of innovative services in RO in the United States.  
There are numerous examples of innovative practices, policies, and 
products that improve health care provision (Darzi & Parston, 2013). The 
methods by which an innovation gains momentum and diffuses (or spreads) 
throughout a specific population or social system over time is typically referred to 
as diffusion of innovation (Rogers, 2003). Diffusion is a passive spread, as 
opposed to dissemination, which is active (Rogers, 2003). Public health 
researchers often overlook the possible lack of diffusion of innovation in efforts to 
improve population health (Darzi & Parston, 2013). Developing a tool to measure 
innovation in RO can be the first step in developing a predictive model for 
improving the diffusion of innovation in the field. This quantitative assessment 
may contribute to the improvement of accessibility and quality of RO services 





Innovation and its implementation are actively studied across many 
disciplines. The implementation of innovative methods in health care and how 
these methods reach the general population is an active field of research. For 
example, the researchers who undertook the Global Diffusion of Health Care 
Innovation study investigated the effects of rapid adoption of innovations on 
public health worldwide (Darzi & Parston, 2013). Parston et al. (2015) identified 
three phases of change management: (a) creating a climate for change by having 
vision, strategy, and a specific agency to promote diffusion, transparency, and 
communication channels; (b) engaging and enabling the whole organization by 
having incentives and rewards; and (c) implementing and sustaining by making 
time and space for learning. The authors emphasize that implementing change in 
health care is both an art and a science (Parston et al., 2015). Parston et al. 
explored quantitative and qualitative parameters that affect innovative technique 
implementation in a variety of socio-demographic environments. In health care, 
the adoption of innovative techniques is not an academic exercise, it can save 
lives. 
Clinical effectiveness in RO is by necessity retrospective, and there have 
been no long-term clinical trials for the majority of innovative techniques used in 
health care. The adoption of new techniques is primarily based on reasonable 
theoretical long-term benefits (Chen, 2014). Assessing cancer survivorship as a 
whole using big-data analyses and defined value is still ongoing (Nardi et al., 
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2016). Smith et al. (2017) discussed the definition of the value of innovation 
implementation from multiple stakeholders and how scientific evidence enters the 
marketplace of RO. Value can mean (a) societal value, such as lost wages, lost 
productivity, and willingness to pay; (b) care value, such as disease control, 
quality of life and long-term theoretical benefits; or (c) system value, such as 
incremental costs, budget impact, and affordability. Nardi et al. (2016) 
investigated the value of comprehensive cancer centers designated by the National 
Cancer Institute (NCICCC). The authors found that for specific cancers, such as 
hepatobiliary, lung, pancreas, gastric, breast, cervical, oral, and colorectal cancer, 
patients had a 20-30% higher 5-year survival when treated at an NCICCC (Nardi 
et al., 2016). NCICCCs are disproportionally located in the Eastern United States, 
which means that for many patients, it is simply not an option to receive treatment 
at these facilities (Nardi et al., 2016). Additionally, many health care plans do not 
cover services at university hospitals or NCICCCs at all (Nardi et al., 2016). The 
majority of Americans, therefore, do not have access to centers that provide better 
cancer outcomes, either because of geographical limitations or because their 
insurance does not cover treatment at institutions with proven better outcomes 
(Nardi et al., 2016). Lack of access to care is one of the many challenges in the 
contemporary United States, and there are no existing studies addressing this issue 
in the field of RO, according to the review of the literature. This study measured 
the accessibility of innovative services in RO in the United States and attempted 




The field of RO has experienced rapid growth in the past 25 years, with 
technological advancement as the driving force. The need for innovation in health 
care is broadly accepted as necessary, with current innovation considered 
insufficient at this point (Parston et al., 2015). Implementing innovative 
techniques requires significant resources, and community hospitals are trailing 
behind (Nardi et al., 2016; Pfister et al., 2015). Fragmented data on innovation are 
available from vendors and professional societies such as the American College 
of Radiology (ACR) and the American Society for Radiation Oncology 
(ASTRO), but there has been limited analysis of the barriers to developing and 
implementing new technology in RO (Mayo et al., 2016).  
The study of the mechanism by which innovations spread geographically 
and across time is of particular interest in health care and is an active field of 
research. These diffusion patterns are explained using various theoretical models, 
one of which is the diffusion of innovation theory, as described by Rogers (2003). 
Diffusion patterns can be assessed by sampling a variety of stakeholders. In this 
study, the problem of diffusion of innovation was addressed from the point of 
view of medical physicists (MPs), who are responsible for the acceptance, 
commissioning, and implementation of innovative techniques in RO. MPs are 
emerging into leadership positions in RO facilities across the United States, not 
only as technical experts but as the leaders in quality management (Delis et al., 
2017). In the study, MPs were evaluated as the adopters of innovations in RO. 
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MPs are not passive recipients of innovation: They seek innovations, assess them, 
find meaning in them, develop positive or negative opinions about them, gain 
experience with them, complain about them, work around them, modify them, and 
circle back to the beginning, beginning the process once again (Rogers, 2003). 
The main adopter categories may be broadly defined as innovators, early 
adopters, early majority, late majority, or laggards (Rogers, 2003). There is 
extensive literature on how cognitive and social psychological antecedents affect 
the individual’s adoption (Greenhalgh, Robert, Macfarlane, Bate, & Kyriakidou, 
2004). The psychological antecedents included in this study were motivation, 
appreciation, self-efficacy and leadership style.  
As discussed in the “Background” section, innovative techniques are not 
accessible equally by all patients, as they are typically available at higher rates in 
university hospitals or urban centers (Pfister et al., 2015). This lack of access is 
directly related to inferior survival outcomes (Nardi et al., 2016). Jacobs et al. 
(2016) studied the implementation frequency of innovative techniques in the 
Netherlands and found a wide range across all centers. They found differences 
between university and community hospitals and emphasized the lack of national 
recommendations for prioritizing innovations, setting goals, and societal 
interventions as long-term solutions (Jacobs et al., 2016). There is a literature gap, 
however, on the extent of accessibility of innovations in RO in the United States 
and its impact on public health. The accessibility of innovative services in RO 
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across the United States as an indicator of public health outcomes was further 
assessed in this study by exploring the role and involvement of MPs. 
Purpose of the Study 
The purpose of this study was to investigate the accessibility of innovative 
services in RO in the United States and assess possible diffusion patterns. These 
patterns were used to create a predictive model of the factors that may affect MPs’ 
role in the diffusion of innovation. An Internet-based survey was conducted with 
a convenience sample of MPs practicing in RO in the United States. A 
quantitative cross-sectional analysis of survey data was conducted to gain insight 
on the accessibility of Food and Drug Administration (FDA)-approved innovative 
techniques in RO. The dependent variable was innovation score, defined as the 
number of techniques available to or purchased by a department divided by the 
number of techniques used clinically, weighed by partial implementation factors. 
Independent variables were geographic location; practice details (university 
affiliation, reporting structure, size of physics group); demographics (age, gender, 
DABR status, residency status, meeting attendance, and education level); and 
context-specific psychological antecedents (motivation, appreciation, and 
leadership). 
Research Questions and Hypotheses 
The research questions (RQs) and hypotheses were as follows: 
RQ 1: What are the differences in accessibility to innovation in RO based on 
location and type of practice in the United States? 
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RQ 2: What are the statistically significant factors (demographics, practice details, 
context-specific psychological antecedents) that predict the accessibility to 
innovation in the RO clinic? 
RQ 3: What are the statistically significant barriers that MPs practicing in RO in 
the United States face in implementing innovations?  
Hypothesis 1a 
H1a0: There is no statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
H1a1: There is a statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
Dependent variable: innovation score (continuous). 
Independent variable: university affiliation (categorical, two levels: has 
university affiliation, does not have university affiliation). 
Hypothesis 1b 
H1b0: There is no statistically significant difference in the accessibility to 
innovation in RO between metropolitan and nonmetropolitan hospitals. 
H1b1: There is a statistically significant difference in accessibility to 
innovation in RO between metropolitan and nonmetropolitan hospitals. 
Dependent variable: innovation score (continuous). 





H20: There are no statistically significant factors predicting innovation 
score. 
H21: There are statistically significant factors predicting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: reporting structure, size of physics group, age, 
gender, DABR status, residency status, meeting attendance, education 
level, leadership (categorical), appreciation, and motivation (continuous). 
Hypothesis 3 
H30: There are no statistically significant barriers affecting innovation 
score. 
H31: There are statistically significant barriers affecting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: barriers (continuous). 
Theoretical Framework for the Study 
“Evidenced-based decision making” is a frequently used phrase in health 
care fields, yet research shows a disconnect between strong scientific support and 
diffuse clinical usage. Pedersen (2015) discussed that health care fields are 
different in their adoption of innovations due to contextual sense-making: 
engagement, materialization and scientification of innovations provides meaning 
to users. Wisdom, Chor, Hoagwood, and Horwitz (2014) defined innovation 
adoption as a complex quality improvement intervention and categorized the 
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mechanistic constructs for the individual to accept innovation and implement it in 
their organization; adoption of innovations is a dynamic process. The unit in this 
study was MPs. The MPs, as individuals, accept or reject innovations and in turn 
facilitate their RO departments in fully utilizing innovations. The assessment of 
the role the MPs play in the diffusion of new products and practices across the 
modern RO clinic health care system in the United States was studied by 
measuring diffusion patterns of these products and practices. Diffusion is defined 
as “the process in which an innovation is communicated through certain channels 
over time among the members of a social system” (Rogers, 2003, p. 5). Rogers 
developed the diffusion of innovation theory in 1962 (Rogers, 2003). The theory 
is based on principles of communication of participants in a social system 
(Rogers, 2003). There are four elements that influence diffusion: the innovation 
itself, the communication channels, time, and the social system (Rogers, 2003).  
In health care, clinical practices are often labeled evidenced-based, yet 
there is a significant gap between clinical practice and recent scientific 
developments. Health care innovations are not simple to implement in most 
clinical settings and require differential resource allocation across multiple levels 
of the organization. Omachonu and Einspruch (2010) developed a health care-
specific conceptual framework involving various stakeholders such as physicians 
and caregivers, patients, organizations, and regulatory agencies. Physician 
acceptance, the complexity of innovation, partnerships and collaboration, 
organizational culture, regulatory acceptance, and organizational leadership all 
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contribute to the probability of acceptance of an innovation (Omachonu & 
Einspruch, 2010). In the field of RO, there has been a broad discussion on how 
technological advances can lead to improved patient outcomes, and stakeholders 
are encouraged to embrace innovation (Chetty et al., 2015). Yet there is no 
framework to quantify or improve the accessibility of innovative techniques. For 
this study, accessibility of innovative RO services was measured using the 
innovation score, as described  in the “Nature of the Study” and “Definitions” 
sections that follow. 
Nature of the Study 
This study was a quantitative numerical assessment of the extent of 
accessibility of innovative techniques across the United States. The dependent 
variable was the accessibility of innovative techniques: how many end-users have 
each technique, how many of them use it, and to what extent. It is common to 
have partial implementations of innovative technologies (Smith et al., 2017). For 
participants who did not use techniques that were available to them, influencing 
variables were investigated. Correlating the accessibility with the type of hospital 
revealed if community hospitals were trailing behind. Reviewing the zip code 
entries relative to the innovation score revealed if rural areas were indeed less 
likely to utilize innovative techniques. Age, gender, DABR status, residency 
status, meeting attendance, and education level of the MPs and correlation with 
the availability of innovative techniques revealed how these factors affect 
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innovation. This information is pertinent to overcoming real and perceived 
barriers in technology implementation in RO. 
In 2018, the AAPM directory listed approximately 7,500 members in total, 
and approximately 5,500 members are listed as active in the United States (not 
student, retired, associate, or corporate members) (American Association of 
Physicists in Medicine, 2018). Seventy-seven percent of the membership reported 
being active in RO (American Association of Physicists in Medicine, 2018); thus, 
there were about 4,200 eligible MPs. The survey was posted on LinkedIn, the 
MedPhysUSA user forum, and the AAPM Blackboard forum. The MedPhysUSA 
is a listserv hosted by Wayne University. It is a highly active online community 
for MPs, where surveys are frequently posted, with over 4,000 members. Users 
must subscribe, and there are volunteer moderators. Unofficial surveys typically 
garner an approximate 5-10% response rate and official surveys an approximate 
30-35% response rate. (American Association of Physicists in Medicine, 2017) 
Considering this response rate and the estimated number of AAPM members, 
approximately 200 responses were expected for this survey.  
Definitions 
American Association of Physicists in Medicine (AAPM): A scientific and 
professional organization composed of more than 8,000 scientists whose clinical 
practice is dedicated to ensuring accuracy, safety, and quality in the use of 
radiation in medical procedures such as medical imaging and radiation therapy 
(American Association of Physicists in Medicine, 2019) . 
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Context-specific psychological antecedents: For the purposes of this study, 
motivation (the internal process that makes a person move toward a goal), 
appreciation (recognition), and leadership. 
Diffusion of innovation: The study of the spread of new ideas and 
technologies among individuals and groups (Rogers, 2003). 
Diagnostic radiology (DR): The field of medicine that specializes in the 
diagnosis of disease using ionizing and non-ionizing radiation (American College 
of Radiology, 2011). 
Intensity-modulated radiation therapy (IMRT): A subset of advanced 
methods used in RO to manipulate the area of treatment and conform to the shape 
of individualized tumors and spare critical organs (National Cancer Institute, 
2011). 
Innovation: For the purposes of this study, innovation will be broadly 
defined to cover products (for example, new technology, inventions, drugs, etc.); 
practices (ways of working, clinical protocols, workforce changes, etc.); and 
policies (those things that regulate/influence the use of products and practices). 
The idea that an innovation is “new” is relative: It is defined as previously 
unknown to the relevant unit, not new on an absolute time scale (Rogers, 2003). 
Innovation Score: The total score of measured innovation indicators for 
product, technology, and organizational innovation. This is a continuous variable. 
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Innovation Utilization Score: The total score of measured innovation 
utilization indicators for product, technology, and organizational innovation. This 
is a continuous variable. 
Medical oncology (MO): The field of medicine that specializes in the 
treatment of malignant cancers using pharmaceutical agents (National Cancer 
Institute, 2011). 
Radiation oncology (RO): The field of medicine that specializes in the 
treatment of malignant cancers using ionizing radiation (National Cancer Institute, 
2011). 
Assumptions 
There are inherent assumptions for this study. As primary data were 
collected, it was assumed that enough MPs will participate in the study to achieve 
statistical significance or at least make the results as representative as possible. It 
was also assumed that participants answered truthfully to all the questions of the 
study. Further, it was assumed that MPs play a vital role in the diffusion process. 
Scope and Delimitations 
It is important to note the difference between availability and accessibility. 
Availability of innovative techniques is undoubtedly essential. After all, if 
something is not available at all, it cannot be used and implemented. Yet the 
availability of innovative techniques in RO would be more of interest in 
marketing studies, not public health. The focus of this study is on accessibility, in 
the context of equitable distribution when taking into account demographic 
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composition, urbanicity and under-served populations (World Health 
Organization, 2018). 
The survey was sent to the entire database of the MedPhysUSA listserv, 
the AAPM Blackboard, and also posted on LinkedIn. Only MPs practicing in RO 
were included. Participants practicing in U.S. territories or internationally were 
excluded. Participants with both Master’s and Doctoral degrees were included. 
Participants were assumed to be fluent in English. 
Limitations 
Selection Bias 
A possible source of selection bias is the exclusion of physicists who are 
not participating in the online forums mentioned in the “Nature of the study” 
section. This possible selection bias was minimized by using LinkedIn in a 
snowball fashion, to attempt to reach MPs who do not participate at the 
MedPhysUSA or AAPM Blackboard. Similarly, MPs in rural community 
hospitals may have been too embarrassed to participate, if they feel the 
technology they are utilizing is not adequate. Both of these could be a serious 
source of error, as the MPs in the areas with the most need for new technology 
may not participate. To minimize selection bias, results were reviewed in total and 
in a weighted average from university and community centers, based on known 




One of the possible sources of information bias in this study was recall 
bias. Szklo and Nieto (2014) define recall bias as inaccurate recall of past 
exposure. In the context of this study, the respondents may have inaccurately 
recalled the exact details of the implementation of new techniques. The recall bias 
may be entangled with social desirability bias. MPs are highly skilled and highly 
paid professionals, and admitting that they have something available but not using 
it clinically may be ignominious. This may have influenced them to report that 
they are using a technique, or that they have been using it more than what is 
actually the reality. Questions were posed on a sliding scale in an attempt to make 
it more likely for the respondents to answer more truthfully. 
Confounding 
University affiliation and urbanicity were assessed as possible 
confounders for the study. All these factors may affect both the exposure and the 
outcome separately, and they are not directly in the causal pathway. 
Statistical Limitations 
Based on the expected participant number, 5% chance of Type I error and 
20% chance of type II error is reasonable. The statistical power of 80% is a 
reasonable initial goal as well Type II errors, not detecting an effect that is 
actually there, or false negative, have more significant social implications than 
Type I errors in this study. Not detecting an under-performance in community and 
rural RO centers would lead to lack of supplemental efforts from AAPM to boost 
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their utilization of new techniques. This would be a disservice to the patients as 
discussed in the section below.  
Significance 
There is a limited ability for hospitals to purchase innovative techniques, 
as RO medical devices are extremely expensive. Even though there is insurance-
based reimbursement, the capital investment is beyond reach for many hospitals. 
For example, a linear accelerator costs $1.5 million to $6 million, and the 
innovative techniques under consideration cost $50,000 to $500,000 (Modern 
Technology, n.d.). These capital investment amounts require years of strategic 
planning and significant budget amounts. Since RO treatments are delivered daily 
over several weeks, patients commonly select facilities close to their area of 
residence (Pfister et al., 2015). Innovative techniques provide an improvement in 
survival; thus disparities in accessibility to these innovative techniques is a public 
health problem. 
Survival rate numbers have significantly improved over the past ten to 
twenty years on the global level, and the reason is largely attributed to improved 
targeting methods, through the use of innovative techniques such as IMRT 
(Cancer Research UK, 2015). Providing RO care of the highest quality to all 
patients by improving the utilization of innovative FDA-approved techniques can 
contribute to the improvement of accessibility and quality of RO services across 
the United States and subsequently improve cancer outcomes. Better health 
outcomes are directly related to a gain in hours worked and an increase in 
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individual income up to 30% (Marquez & Farrington, 2013). These results are 
even more pronounced in low-income settings, when health costs may be out of 
pocket. Declining health costs is often a reason quoted for crossing the poverty 
line (World Health Organization, 2010). Healthier people are more efficient in the 
workplace, and this affects government and commercial sector alike (General 
Electric, 2014). Innovative techniques are available, but may not be accessible to 
all patients. There are enormous inequalities within and between nations in health 
care in general and the public health effects of this at the global level are being 
investigated by the Global Diffusion of Health care Innovation study (Darzi & 
Parston, 2013). This public health problem is in alignment with the ninth essential 
public health service to "evaluate effectiveness, accessibility, and quality of 
personal and population-based health services" (Centers for Disease Control and 
Prevention, 2017). There are currently no studies measuring the accessibility of 
innovative services in RO in the United States. Measuring the accessibility of 
innovative services in RO and developing a predictive model to offer a foundation 
to improve it is a contribution to positive social change. 
Summary 
The National Cancer Institute (2018a) estimated that in 2018 alone, there 
were 1.7 million new cancers and approximately 609,000 deaths due to this 
disease in the United States. Cancer incidence in the United States is 439.2 per 
100,000 people, and mortality is 163.5 per 100,000, with higher mortality in men 
(196.8 per 100,000) than women (139.6 per 100,000). Mortality is highest in 
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African American men (239.9 per 100,000). Throughout their lifetimes, 38.4% of 
Americans will be diagnosed with cancer, leading to $147.3 billion in national 
expenditures for cancer care. As the population ages, the number of new cancer 
cases per year is predicted to be 23.6 million by the year 2030. There are 
quantitative demands, such as the number of cancer centers and relative staff 
(Aneja & Yu, 2012; Yang et al., 2014), and the challenges of rural cancer care in 
the United States is well documented, with multiple studies correlating driving 
distance to RO center with treatment decisions and outcomes (Charlton, 
Schlichting, Chioreso, Ward, & Vikas, 2015). 
There are approximately 2,500 RO centers in the United States, 5,500 
radiation oncologists, and 4,000 MPs specializing in RO (Ballas, Elkin, Schrag, 
Minsky, & Bach, 2006). Little is known, however, about the different techniques 
used in every RO center. While the majority of patients are treated using national 
standards (National Comprehensive Cancer Network, n.d.), the guidelines provide 
a wide range of options, allowing customized clinical decisions.  
Even though products may receive FDA approval, little is known about 
their implementation in the clinical setting. It is well demonstrated that the 
majority of health care spending is due to the cost of technological innovations 
(Dybczak & Przywara, 2010). In turn, there are many publications on how 
specific innovations improve output, such as survival, toxicity, safety, service, 
efficiency, or cost-effectiveness. In the next chapter, a literature review was 
conducted on the diffusion of innovation in health care in general, and RO 
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specifically. Systematic reviews and cross-sectional studies were reviewed. 
Results were thematically synthesized to the diffusion of innovations in health 
care in general, diffusion of specific innovations in RO, effects of innovations on 





Chapter 2: Literature Review 
Introduction 
The purpose of this study was to investigate the accessibility of innovative 
services in RO in the United States and assess possible diffusion patterns. These 
patterns were used to create a predictive model of the factors that may affect MPs’ 
role in the diffusion of innovation in RO. From the literature review presented in 
this chapter, it is evident that RO has a push-pull relationship with innovation. 
Innovation is readily available, yet not extensively utilized, at least not in all 
settings. For innovative technologies that are purchased as part of a package, as 
well as those with no upfront costs, health care professionals appear hesitant to 
undertake implementation. To some extent, the hesitancy to embrace innovation is 
understandable, as outcomes have been improving using traditional techniques 
(Chen, 2014; Jagsi et al., 2012; Smith et al., 2017). For practitioners in suburban 
or rural areas, who are not in direct contact with opinion leaders and research 
findings, it may indeed appear this way that outcomes are improving with 
continuous use of traditional techniques. Even though errors leading to patient 
death exist in all medical fields, in RO there are many catastrophic errors that can 
occur on any day of the long treatment path, typically lasting weeks. Despite the 
importance of this topic, there are currently no assessments of the diffusion of 




The chapter begins with an overview of the literature search strategy, 
theoretical foundation, and methodology used in the study. In the literature review 
that follows, the theoretical foundation of the study, diffusion of innovation, and 
how it applies to health care and RO are presented. Previously published 
systematic reviews and cross-sectional studies were used to develop a thematic 
synthesis of key literature for the review. Topics include the diffusion of 
innovations in health care in general, diffusion of specific innovations in RO, 
effects on value, effects on quality and outcomes, social impact, and predictive 
parameters. 
Literature Search Strategy 
Walden University Library and Google Scholar were used to conduct 
searches of the literature. Search terms included radiation oncology, oncology, 
diffusion of innovation, early adopters, medicine, health care, radiology, equity, 
and public health. Key words were based on key concepts in previously identified 
published reviews. Diffusion of innovation is sometimes referred to by other 
terms, and thus, similar key word items were also used, such as innovation, 
adoption rate, new technology, and new technology accessibility. The key words 
were combined in various ways using Boolean operators in context--for example, 
early adopters in radiation oncology, new technology in radiation oncology, 
diffusion of innovation in healthcare, new technology in radiation oncology 
innovation, health equity, and accessibility to new technology. After the initial 
review of the results, further parameters were identified that were considered to 
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possibly be influential. Additional searches were conducted using the following 
terms: academic, academic cancer centers, university hospital, community 
hospital, rural/rurality, city/urban/urbanicity, demographics, reporting structure, 
employment type, appreciation, motivation, and leadership. These were combined 
with innovation, adoption rate, new technology, and new technology accessibility 
using Boolean operators as described. Only articles published in English were 
included. The date range was limited to articles published since 2013, with the 
exception of seminal works on the theory of diffusion and well-established 
psychological context-specific antecedents. 
The various search parameters produced over 200 results. These were 
screened manually and articles were excluded when not directly pertinent. 
Additional studies were identified by following the references. This step was 
performed by using the “cited by” function in Google Scholar and by manually 
looking up references within the selected articles, when applicable. Due to the 
narrow focus on RO, the search was expanded to other fields of medicine and 
health care. Studies were included when they addressed diffusion of innovation 
patterns of clinical innovations in other medical fields, especially DR and MO, 
which are the closest fields to RO. Results were thematically analyzed as 
described in the following sections. 
Theoretical Foundation 
Health care practitioners have a long and beguiling history of accepting or 
rejecting innovations. The basic principles of hygiene were developed from 
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Hippocratic medicine in ancient Greece. These principles may be considered 
elementary today, but they were innovative at the time. They received 
considerable criticism and skepticism  and, to this day, are not accepted in certain 
parts of the world (Tountas, 2009). More recently, the resolution of scurvy was 
much delayed in the 18th century, as the British Royal Navy stubbornly refused to 
accept and diffuse the practice of vitamin C supplementation. The fable may be 
well known to public health practitioners, but the details of the delayed 
implementation circa 1793-1800 as described by Vale (2008) paint a picture full 
of political intrigue. The influence of a few forward-thinking physicians was the 
catalyst needed for the widespread adoption of vitamin C against scurvy (Tountas, 
2009). Public health history is full of similar examples, from the distant past until 
present day.  
Schumpeter (1989) described the continuous generation of innovations as 
“creative destruction” (p. 83) and concluded that adaptation to innovation is the 
rule, not the exception. Increasing health care costs, aging populations, and more 
demanding consumers are compelling organizations to offer innovative solutions 
(Herzlinger, 2006; Varkey, Horne, & Bennet, 2008). However, less than 50% of 
all evidence-based practices are effectively implemented in the health care system 
(Alexander & Hearld, 2011; M. Jacobs et al., 2017). Innovation implementation is 
an area that needs improvement in health care in general and in RO as well. 
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Diffusion of Innovation 
Rogers first introduced diffusion of innovation theory in 1962, while 
studying rural sociology in the Midwestern United States and the adoption rates of 
hybrid seeds in the area (Rogers, 2003). He combined over 500 studies from a 
variety of fields, including anthropology, early sociology, rural sociology, 
education, industrial sociology, and medical sociology, and the synthesis was his 
seminal diffusion of innovation theory (Rogers, 2003). The theory has expanded 
into social network analysis and is currently frequently used in communications, 
marketing, development studies, health promotion, organizational studies, 
knowledge management, conservation biology, and complexity studies, 
particularly in the medical field and health communication studies (Rogers, 2003). 
There are five stages in implementing an innovation, as described by Rogers 
(2003):  
1. Knowledge. The individual is exposed to an innovation for the first time 
but does not have significant knowledge about the specifics of the 
innovation. There is not yet any motivation from the individual to pursue 
the innovation. 
2. Persuasion. The individual is actively interested in the innovation and is 
beginning to consciously explore related information/details. 
3. Decision. The individual begins to study the advantages and disadvantages 
of using the innovation and decides whether to either adopt or reject the 
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innovation. This stage is the most individualistic and thus the most 
difficult to collect empirical evidence on. 
4. Implementation. The individual begins to use the innovation to a smaller 
or larger degree, depending on the situation. The individual also 
determines their personal opinion on the usefulness of the innovation and 
may research additional information on the innovation. 
5. Confirmation. The individual finalizes the decision to continue using the 
innovation. This stage is both intrapersonal and interpersonal, 
confirmation the group has made the right decision.  
The degree by which innovation is accepted by individuals depends on 
both the individual’s characteristics and on the characteristics of the organization 
in which the innovation is going to take place  and typically follows an S-curve 
(Rogers, 2003). Rogers classified individuals within a social system as being in 
one of five categories: 
1. Innovators. This group is willing to take risks, has the highest social 
status, has financial liquidity, is social, is in touch with scientific 
sources, and has frequent interaction with other innovators. They have 
high-risk tolerance for adopting new technologies. 
2. Early adopters. These are typically the opinion leaders among all the 
categories. They may have higher social status, financial freedom, 
higher education and may be more socially open than late adopters. 
They are more thoughtful in adoption choices than innovators. 
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3. Early majority. This group adopts an innovation after significantly 
larger amount of time than the innovators and early adopters. They 
may have above average social status, contact with early adopters and 
are less likely to hold positions of opinion leadership in a system. 
4. Late majority. This group adopts an innovation much later than the 
average participant. They view innovation with cautiously and with a 
high degree of skepticism and even after the majority of society has 
adopted the innovation. The Late Majority group are below average 
social status, have little financial liquidity, in contact with others in 
late majority and the early majority and little opinion leadership.  
5. Laggards. This group is the last to adopt an innovation. Contrary to the 
other categories, Laggards show little to no opinion leadership. 
Individuals belonging to this group typically have a strong dislike for 
change-agents. Laggards typically tend to be focused on "traditional 
ways," have the lowest social status, lowest financial liquidity may 
typically be older than adopters, and are in contact with only family 
and close friends.   
Rogers (2003) recognizes five qualities that determine the success of an 
innovation.  
1. Relative advantage. This is the degree to which an innovation is 
perceived as better than what is currently available, relative to the 
actual users, for example in terms of economic advantage, social 
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prestige, convenience, or satisfaction. If the innovation has a high 
perceived relative advantage, it will get adopted at a more rapid pace. 
Relative advantage is subjective and may carry a different meaning for 
different individuals or groups. It depends on the particular needs and 
dynamics of the user group.  
2. Compatibility with existing values and practices. This is the degree to 
which an innovation is perceived as being consistent with the values, 
past experiences, and needs of potential adopters. If innovation is 
comparable with the group's values, norms or practices, it will be 
adopted more rapidly.  
3. Simplicity and ease of use. This is the degree to which an innovation is 
perceived as difficult to understand and use. If an innovation is simple 
and easy to understand it will be adopted more rapidly than 
innovations requiring increased understanding and new skills.  
4. Trialability. This is the degree to which an innovation can be 
experimented with on a limited basis. If innovation can be trialed out 
by the individual considering it, without being bound in it, it will be 
more likely that the individual will consider it.  
5. Observable results. If the results of an innovation are easily visible to 
users, they are more likely they are to adopt it. When the results are 
clearly visible, there is lower uncertainty and increased peer discussion 
of a new idea, as more people seek information about the innovation. 
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According to Rogers (2003), these five qualities determine between 49 and 87% 
of the variation in the adoption of new products. 
Reinvention is one of the leading principles in the diffusion of innovation. 
The success of an innovation is highly dependent on how well it evolves to meet 
the needs of the more risk-averse individuals in a population. The innovation does 
not have to be new in an absolute sense; it just has to be new to the individual. 
Organizational and Personal Antecedents 
Organizational and personal characteristics dynamically influence the 
outcome of successful innovative behavior. The organizational and personal 
constructs related to innovation are increasingly investigated across many 
research fields such as information systems, psychology, organizational and 
management science and multidisciplinary science (Najaftorkaman, Ghapanchi, 
Talaei-Khoei, & Ray, 2015). The organizational constructs affecting innovation 
were summarized by Wisdom et al. (2014) to be absorptive capacity, leadership 
style, networking, culture, size and structure, social climate, social network, 
training readiness and effort, and traits and readiness for change. The individual 
characteristics affecting innovation were summarized by Wisdom et al. (2014) to 
be affiliation with organizational culture, attitudes, motivation, readiness for 
improvement and reward, feedback on execution and fidelity, awareness, social 
networking, knowledge/skill, competence, and demographic factors. Context-
specific psychological antecedents, such as appreciation, motivation, and 
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leadership are also well-studied to influence the individual’s response to 
innovation (Greenhalgh et al., 2004; Pedersen, 2015; Wisdom et al., 2014). 
Adoption and Diffusion of Innovation in Health Care 
The adoption and diffusion of innovative services in health care is distinct 
from other fields. The lack of effective implementation of innovations in health 
care affects the lives of patients. Reinhardt, Hietschold, and Spyridonidis (2015) 
analyzed Roger’s classical diffusion of innovation framework and how it pertains 
to health care. The authors investigated the five qualities that determine the 
success of an innovation mentioned before and found  them to be valid in the 
health care setting: relative advantage translates to focus on “hard” numbers, 
compatibility translates to leaving non-core processes unchanged, complexity 
translates to using easy-to-use innovations and shifting the point of care, 
trialability translates to making parts of the innovation trialable in a small scale, 
and observability translates to successful communication of outcomes to all 
relevant stakeholders. The authors also pointed out the distinction between 
individuals and organizations as highly important in the health care setting. 
Individuals may be innovative in one or many domains, thus making them more 
likely to adopt an innovation in their health care role, but they can also be 
resistant when confronted with barriers. On the other hand, organizations are 
motivated by gains and resistance on the organizational level may become evident 
when the implementation of an innovation is misinterpreted to coincide with 
individual or group loss of power or status. The authors concluded that the various 
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stakeholders in health care form a complex network, and a wide array of different 
professions needs to collaborate to ensure widespread use of an innovation. They 
also emphasized that formal and informal partnerships are often needed and that 
champions or “celebrity hospitals” are influential in innovation adoption and 
diffusion.                   
Methodology 
A broad review of the selected articles was conducted. The methods used 
can be categorized into two main groups: systematic reviews, cross-sectional 
studies, and surveys. 
Systematic Reviews 
In systematic reviews, authors collect and summarize previously published 
studies and present it in a concise format. Even though there is no clear definition 
of what constitutes a systematic review, the main characteristics are typically (a) 
clear objectives with specific methodology that can be reproduced by others; (b) 
an exploration of existing literature including methodology to attempt to find all 
possible studies fitting the eligibility criteria; (c) validity assessment of the studies 
included, for example for bias etc; and (d) a presentation of the results as a 
synthesis (Moher et al., 2015). The use of systematic reviews is increasingly 
common, and the quality of these reviews is improving through reporting 
standardization, especially after the adoption of the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses for Protocols (PRISMA-P). Strengths of 
systematic reviews include more precise estimates of effects than those derived 
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from individual studies and a cohesive approach to the research problem. The 
main limitations are possible erroneous conclusions if all studies were not 
identified. For example, Parston et al. (2015) did a systematic review of 
successful innovations in health care with a significant impact on public health 
and assessed the factors affecting rapid adoption. In another example, M. Jacobs 
et al. (2017) conducted a literature review on the frequency of output evaluation 
of innovations in RO. Output was defined as survival, toxicity, safety, service, 
efficiency or cost-effectiveness. The authors looked for publications in three 
ways: innovations in general health care, radiotherapy-specific innovations, i.e., 
organizational innovations and general implementation of innovations, and 
innovations per tumor group/radiotherapy technique. Smith et al. (2017) did a 
review of the current appropriateness of the use of advanced technologies for 
radiation therapy and surgery in oncology. They focused their study on the 
definition of the value of innovation implementation from multiple stakeholders 
and how scientific evidence enters the marketplace of radiation oncology. The 
authors specifically studied the adoption rate of two distinct innovative 
techniques, IMRT in the 1990s and early 2000s and proton therapy in the 2000s. 
Some of the articles cited in these systematic reviews are not explicitly mentioned 
in this section, yet will be used in the synthesis section below.  
Cross-Sectional Studies 
Cross-sectional studies are a type of observational study that analyzes data 
from a population or population sample at a specific point in time and draws 
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conclusions on the state of affairs at that moment in time. Strengths of this type of 
study include a relatively low cost, rapid completion, and relative ease to achieve 
large sample sizes. Limitations of cross-sectional studies are the inability to 
determine causation and follow through to develop changes in the observed 
patterns (Cresswell, 2018). For example,  Jacobs et al. (2016) studied the degree 
of innovation routinely implemented in the Netherlands by doing a descriptive 
cross-sectional study. The authors used semi-structured interviews to collect 
information on product innovation (number of introductions of new or 
significantly improved treatments, number of new positioning devices, percent of 
patients on phase I-II randomized trials, percent of patients in phase III trials), 
technological innovation (frequency of implementation of new medical devices, 
number of products purchased), market innovation (percentage of patients from 
outside the market area, percent of referring hospitals) and organizational 
innovation (new practices for organizing procedures, new methods for organizing 
work responsibilities, new methods for organizing external relationships with 
organizations or public institutions). Pfister et al. (2015) used Surveillance, 
Epidemiology, and End Results (SEER) Medicare data to study risk-adjusted 
mortality by cancer category in the Medicare population and investigated the 
difference in outcomes based on university affiliation status. Pollack, Soulos, and 
Gross (2015) studied peer exposure the adoption of a new cancer treatment 
modality (breast brachytherapy) by using SEER data and correlated the exposure 
of early brachytherapy adopted among non-early adopters by investigating their 
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shared patients. Nardi et al. (2016) did a cross-sectional analysis of five-year 
survival between specialty and non-specialty cancer hospitals. Keown et al. 
(2014) did a two-phase qualitative and quantitative cross-sectional study in eight 
countries (Australia, Brazil, England, India, Qatar, South Africa, and the United 
States) and compared cultural factors enabling health care innovation. 
Surveys 
While there is no research done on validating web-based surveys 
specifically on MPs, Dykema, Jones, Piché, and Stevenson (2013) analyzed the 
use of web-based surveys in clinicians and other health care providers and 
concluded to achieve good response rate, high incentives are needed. The authors 
summarize their findings to equate web-based surveys to traditional ones, 
assuming a rigorous methodology and clarity in result reporting.  
Literature Review Related to Key Concepts and/or Variables 
Results of the literature review were thematically synthesized. Diffusion 
of innovations in science and health care in its entirety is presented. Subsequently, 
RO-specific implementations are assessed. Each of the following categories is 
then presented as separate entities: effects on value, quality and outcomes, social 
impact and predictive parameters. 
Diffusion of Innovation in Science 
Innovation and science have a tight-knit relationship. The terms science, 
technology, and innovation are frequently used interchangeably. For example, the 
United Nations Educational, Scientific and Cultural Organization (UNESCO) has 
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an entire program devoted to science, technology, and innovation, as means for 
economic development and social progress (UNESCO, 2018). In the classic linear 
models discussed by Eizagirre, Rodríguez, and Ibarra (2017), there is an 
expectation that funding science will lead to innovation, through technological 
advancements. However, this narrow approach fails to include socio-economic 
context and the role of government in allowing deviation from traditional models 
so mutually responsive co-responsibility can emerge between social actors. 
Eizagirre et al.(2017) concluded that the relationship between science and 
innovation is converging to inertia and a new paradigm is needed. The blurring of 
the lines between neoliberalism and economization in the United States is 
blatantly apparent when reviewing the accessibility of innovative services in 
health care (Berman, 2014). 
Diffusion of Innovation in Health Care in General 
Over the past twenty years, there has been an exponential increase in 
innovative policies, products, and practices aiming to increase life expectancy, 
quality of life, effectiveness of treatment, efficiency of treatment, and equity of 
delivery (Frenk, 2013). How innovations are actualized to improve public health 
is often referred to as translational research. The time lag between an introduction 
of an innovation and its diffuse clinical practice was estimated to be on average 
17 years, however the way this time lag is measured varies depending on content 
and exact research questions (Morris et al., 2011). It is logical to attempt to 
shorten this time so the benefits can be maximized; in fact there is an extensive 
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body of literature on the individual and organizational characteristics that promote 
acceptance and proliferation of innovation in health care (Parston et al., 2015). 
Different countries are adopting different strategies to do so. Darzi and Parston 
(2013) studied the local context of spreading innovations for eight different 
countries and found substantial differences in cultural dynamics. In the United 
States, the authors found that standards and protocols along with incentives and 
rewards were the most important enabling factors for innovation, followed by 
funding for research development and diffusion, communications channels across 
and beyond health care, transparency of findings and data demonstrating success 
and informatics. Vision and strategy, along with specific resources to identify and 
promote innovation were ranked as the least important parameter for the diffusion 
of innovation among expert users on the panel (Darzi & Parston, 2013). 
The need for innovation in health care is broadly accepted not to be 
sufficient (Harris, Bhatti, Prime, del Castillo, & Parston, 2018; S. R. Jacobs et al., 
2015). There is general agreement that innovation implementation improves 
patient outcomes (Daniels & Capouya, 2017; Parston et al., 2015). There are 
numerous examples of adverse patient outcomes due to ineffective 
implementation of innovation in the health care setting (Reinhardt et al., 2015). 
The majority of criticism against innovation is related to high costs; innovation is 
often described as being too costly, as research and development alone cost 
billions. These simplistic approaches often underestimate the complexity of cost-
benefit and the lower downstream costs of improved health at the individual and 
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societal level (Dzau, Asch, Hannaford, Aggarwal, & Pugh, 2017). There needs to 
be a distinction, however, with low-cost yet proven approaches, especially at low 
resource settings; high-cost innovative approaches are only beneficial if they 
outperform their pre-existing solutions and are affordable enough to lead to 
improved population health. Innovations need to sustainably show benefits to be 
meaningful (Dzau et al., 2017).   
The health care setting provides an excellent field to emphasize the 
difference of the different levels that innovation can take place in. In their seminal 
work on health care diffusion of innovation, Greenhalgh, Robert, Macfarlane, 
Bate, and Kyriakidou (2004) make a health care industry-specific distinction on 
the adoption by individuals and adoption by organizations. Organizational 
innovativeness is affected by the administrative intensity, centralization, 
complexity, internal and external communications, formalization, functional 
differentiation, managerial attributes toward change, managerial tenure, 
professionalism, slack resources, specialization, technical capacity, and vertical 
differentiation. The individual is influenced by general antecedents (tolerance of 
ambiguity, intellectual ability, motivation, values, and learning style) and context-
specific psychological antecedents (values, goals, specific skills, etc.). The 
majority of publications focus on the science of diffusion, and few on the art of 
change (Pedersen, 2015). There are also significant differences in how innovation 
is implemented in low-resource settings (Harris et al., 2018). 
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Diffusion of Innovation in RO 
RO prides itself as a high technology field. Linear accelerators, atomic 
particles, and algorithms work harmoniously to cure cancer. There is currently 
extensive usage of many advanced cutting-edge technologies: (a) computational 
advances using graphics processor units (GPUs), cloud-based methods, and 
parallel processing have improved calculation speed and are being used for 
automated knowledge-based treatment planning; (b) high performance imaging 
systems such as positron emission tomography (PET) allow tumor identification 
and radiotherapy response measurement, and onboard magnetic resonance 
imaging (MRgRT) improves real-time monitoring; (c) heavy particle treatments 
better spare healthy tissues, especially in pediatric populations. However, the field 
has not universally accepted these innovations (Chetty et al., 2015) and little is 
known about the factors that may influence groups and individuals (Pollack et al., 
2015). This may be partly affected by the fact that few publications include the 
term "innovation," while in reality, they are actually describing an innovative 
technique (M. Jacobs et al., 2017). 
M. Jacobs et al. (2015) applied the Delphi method to determine indicators 
for innovation in RO and derived 13 indicators in four categories: 
 Product innovation: number of introductions of new or significantly 
improved treatments, number of new positioning devices for patient 
treatments, number of approved patents, percentage of patients in 
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phase III randomized trials approved by an IRB, percentage of patients 
in phase I-II trials approved by an Institutional Review Board (IRB) 
 Technological innovation: frequency of implementation of new 
medical devices, number of products for which royalties have been 
obtained or which have been sold to the industry, number of regulatory 
agency approved marked products that have been produced by the 
department (for example regulated by the Food and Drug 
Administration (FDA), or the Conformité Européenne (CE)) 
 Market Innovation: percentage of patients from outside the market 
area, number and percentage of new general hospitals that refer to the 
desired patient population. 
 Organizational innovation, new practices and for organizing 
procedures, new methods of organizing work responsibilities and 
decision making, new methods of organizing external relationships 
with other organizations or public institutions 
The authors suggest that these indicators are most useful when measured 
in the past three calendar years. These indicators are useful in an attempt to study 
innovation in RO. Yet, there is currently no study that systematically quantified 
the diffusion of innovation in RO in the United States. Innovation implementation 
has been more successfully quantified in the Netherlands with a small number of 
centers. Jacobs et al. (2016) studied 15 Dutch RO cancer centers (75% of the total 
in the Netherlands) and found that they implement on average12 innovations per 
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year (range 5-25). The authors will attempt to repeat at three-year increments. The 
average number is sufficiently large and the authors concluded that Dutch 
radiotherapy centers are highly accepting of innovation. The wide range, 
however, suggests a non-homogenous distribution, which the authors did not find 
to be attributed to academic status. The authors concluded that systematic 
collaboration between centers and a national registry would be beneficial to 
improving innovation implementation even further. 
Value of Innovation 
The definition of value in health care is not very clear. As mentioned 
before, some of these innovations are extremely expensive and frequently out of 
reach for standalone community hospitals. Even though one can argue that the 
investment in innovative technologies translated to increased income for the 
providers and hospitals and to increased quality-adjusted life-years, the math is 
not straightforward in RO. In MO, the development of new pharmaceuticals may 
increase the cost of treatment for new, promising chemotherapy agents directly 
improves outcomes (Roubou & Alexopoulou, 2015). In RO, innovations need 
long-term investments to sustain the appropriate use of the technology in the form 
of upgrades, service contracts, staff education, etc (Smith et al., 2017). There is 
also a broad discussion of reimbursement for innovative techniques. If the 
innovative technique has an associated financial motive, then the decision to 
implement it may be spurious at best. The higher reimbursement rates for IMRT 
discussed previously were certainly a contributing factor to its fast and successful 
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diffusion across the United States. Conversely, some of the innovative techniques 
available reduce the number of total treatments and the overall provider and 
hospital reimbursement. A common example is the use of hypo-fractionated 
versus conventional whole breast irradiation in the United States: despite 
supportive 10-year data from the United Kingdom, only 11% of eligible patients 
received this shorter and less costly regiment in 2008 and 35% in 2013 (Bekelman 
et al., 2014). In the absence of financial incentives, providers are less likely to 
adopt innovative treatments that may improve outcomes but reduce their direct 
financial benefit. In health care in general, value can mean societal value, such as 
lost wages, lost productivity, and willingness to pay, care value, such as disease 
control, quality of life and theoretical long-term benefits, or system value, such as 
incremental costs, budget impact and affordability (Smith et al., 2017). All these 
three constitute a cost-effective ratio to consider an innovative technique to be of 
better value than the established technique, and there is little agreement on the 
calculation of this ratio. Usage of lower cost but better techniques does have 
successful examples from DR. The Joint Task Force on Adult Radiation 
Protection was created by the collaboration between the American College of 
Radiology and the Radiological Society of North America with the purpose 
addressing the public’s concern about exposure to ionizing radiation from medical 
imaging. The Joint Task Force collaborated with the American Association of 
Physicists in Medicine and the American Society of Radiologic Technologists to 
develop standards and launch an extensive awareness campaign under the slogan 
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“Image Wisely” for adults and “Image Gently” for pediatric patients (American 
College of Radiology, 2011). These efforts are focused on optimizing existing 
techniques to limit unnecessary exposure, and often inadvertently highlight the 
limitations of older equipment. Approaches such as this provide a clear statement 
to the market and to practitioners that they need better and different innovations. 
Effects on quality and outcomes. In the field of RO, innovative 
techniques are often implemented based on the “as low as (is) reasonably 
achievable” principle (ALARA). This principle means “making every reasonable 
effort to maintain exposures to ionizing radiation as far below the dose limits as 
practical, consistent with the purpose for which the licensed activity is 
undertaken, taking into account the state of technology, the economics of 
improvements in relation to state of technology, the economics of improvements 
in relation to benefits to the public health and safety, and other societal and 
socioeconomic considerations, and in relation to utilization of nuclear energy and 
licensed materials in the public interest” (Nuclear Regulatory Commission, 2018). 
In RO, innovations are frequently implemented using this principle, in the 
absence of clinical trials, and there is broad agreement that this improves quality 
and outcomes (M. Jacobs et al., 2017). While clinical trials are typically the gold 
standard for evidence-based approaches (Daniels & Capouya, 2017), the 
implementation of innovative techniques using ALARA is extensive in RO 
(Chen, 2014). Since there are no clinical trials to drive nationwide 
recommendations, users can choose their own methods on how to treat patients, 
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within the broad standards described by the National Comprehensive Cancer 
Network (National Comprehensive Cancer Network, n.d.). This leads to 
significant differences in outcomes for different populations and leads to the 
conclusion that quality of cancer care in the United States is inconsistent, with 
patients treated at specialty cancer hospitals having an adjusted 10% lower 
mortality at one year than patients treated at community hospitals (Pfister et al., 
2015). This inequality to access to appropriate cancer care may not be solely due 
to innovations, but it is certainly a parameter (Nardi et al., 2016). Additionally, 
there is little innovation implementation in using big data in RO. Since the advent 
of electronic medical records (EMR), there has been little or no standardization of 
specific field entry. The most basic example is the radiation prescription: after ten 
years of discussion, there is barely a draft in progress (personal communication, 
RO-SSI group, July 16, 2019). This makes data extraction and comparison 
extremely difficult and often meaningless. Data elements such as survival, 
recurrence, diagnosis and staging, provider-reported toxicities, dosimetric data 
from delivered plans, and use of innovative technologies (such as breath-hold, 
image-guided radiation therapy, immobilization devices) are largely missing as 
elements in most EMRs. Extracting this data automatically would lead to self-
evaluation and scoring relative to national standards, thus improving the adoption 
of standards (Mayo et al., 2016). 
Social impact. Different cancer care treatments especially in 
hepatobiliary, lung, pancreas, gastric, breast, cervical, oral, and colorectal cancer, 
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where patients five-year survival is higher by 20-30% for patients treated at 
comprehensive cancer centers designated by the National Cancer Institute 
(NCICCC) (Nardi et al., 2016). These NCICCCs are disproportionally located in 
the eastern United States and major cities across the country (National Cancer 
Institute, 2018b). The average American living in a rural area has to travel an hour 
to reach specialized oncology care, and an hour and a half to reach a university 
hospital (Charlton et al., 2015). Many patients live so far away from an NCICCC, 
they simply do not have the option to seek treatment there. Additionally, many 
health care plans do not cover services at university hospitals or NCICCCs at all 
(Nardi et al., 2016).  This translates to the majority of Americans not having 
access to centers that provide better cancer outcomes, either because of 
geographical limitations or because their insurance does not cover treatment at 
institutions with proven better outcomes. This is one of the many challenges in 
modern America, especially in rural areas. One of the ten essential services of 
public health is to “evaluate effectiveness, accessibility, and quality of personal 
and population-based health services” (Centers for Disease Control and 
Prevention, 2017). The possible lack of diffusion of innovation in RO is a factor 
that is often overlooked in improving population health. Providing RO care of the 
highest quality to all patients by improving the utilization of innovative FDA-
approved techniques wound contribute to the improvement of accessibility and 
quality of RO services across the United States and subsequently improve cancer 
outcomes. This would be a contribution to positive social change. 
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Organizational Predictive Parameters 
Academic affiliation status has been shown to have a positive main effect 
on innovation and accessibility of services, possibly through slack staffing 
resources and increased financial resources (Wisdom et al., 2014). Urbanicity has 
been shown to have a positive effect on innovation and accessibility of services, 
possibly through competition (Angst, Agarwal, Sambamurthy, & Kelley, 2010; 
Charlton et al., 2015). Employment type details and type of practice have an 
unclear relationship with innovation. Organizational structure and climate have 
been shown to influence innovation adoption, possibly through fecund 
management tiers (Angst et al., 2010; Wisdom et al., 2014); the number of 
physicists and reporting structure will be used to assess the organizational 
structure and climate for MPs. 
Individual Predictive Parameters 
Gender has a complicated relationship with innovation and there are 
conflicting results in the literature (Lee, 2016). Recent research focuses on 
entrepreneurship and gender ratios on the executive level and its relationship to 
organizational innovation and success (Belghiti-Mahut, Lafont, & Yousfi, 2016). 
The possible influence of gender in MPs practicing in RO is not certain, and it 
will thus be interesting to include this parameter in the analysis. On the contrary, 
the effects of education and age are well studied. Age typically has a negative 
main effect on innovation adoption (younger people are more likely to adopt 
innovations) and education typically has a positive main effect on innovation 
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adoption (people with higher education levels are more likely to adopt 
innovations) (Arts, Frambach, & Bijmolt, 2011). Social status typically has a 
positive main effect on innovation adoption (people with higher status are more 
likely to adopt innovations) (Rogers, 2003); affiliation with academic institutions 
will be used to assess the social status in MPs. Interpersonal channels typically 
have a positive main effect on innovation implementation (people with more 
intrapersonal channels are more likely to adopt innovations) (Rogers, 2003); the 
number attendances in national meetings will be used to assess interpersonal 
channels in MPs. Organizational structure and climate have been shown to 
influence innovation adoption (people in larger, well-organized groups are more 
likely to adopt innovation) (Wisdom et al., 2014); the number of physicists and 
reporting structure will be used to assess the organizational structure and climate 
for MPs. Motivation and appreciation are two individual characteristics that are 
frequently used to assess the position of the individual in the stages previously 
described by Rogers (2003)  (Wisdom et al., 2014); the sense of appreciation and 
motivation will be directly assessed in the study participants as context-specific 
psychological antecedents. Appreciation and motivation typically have a positive 
main effect on innovation adoption, as they may increase the individual’s 
tolerance of risk (people who feel appreciated and motivated are more likely to 
adopt innovations). Similarly, opinion leadership typically has a positive main 
effect on innovation adoption (people who consider themselves opinion leaders 
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are more likely to adopt innovations) (Arts et al., 2011); volunteering in AAPM 
committees will be used to assess the opinion leadership of MPs. 
Summary and Conclusions 
Innovation implementation is an area that needs improvement in science, 
health care in general and in RO specifically. The diffusion of innovation 
theoretical framework is one of the oldest social science theories, and it is well 
studied in health care, thus grounding the literature review. In this study, the 
results of the literature review were thematically synthesized to diffusion of 
innovations in health care in general, diffusion of specific innovations in RO, 
effects on value, effects on quality and outcomes, social impact, organizational 
and personal predictive parameters. 
The state of diffusion of innovation in RO in the United States is currently 
not measured, but it is suspected to follow the low rates experienced in other 
health care fields. There are many underutilized innovations in RO that can 
enhance patient and staff safety and improve patient outcomes simultaneously. 
Developing a tool to measure innovation will be the first step in developing a 
predictive model to improving its diffusion. There is currently no systematic 
quantification of diffusion of innovation in RO in the United States, and no 
existing secondary dataset that can be used to extract this information. 
Understanding the individual and organizational real and perceived barriers to 
implementing innovations would create the framework to overcome them. If 
something is not measured, there is no opportunity to study it and further improve 
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it. There needs to be enhanced understanding of how innovative techniques are 
adopted in RO specifically and assess any disparities in technology 
implementation in RO in the United States.  
To this end, the following chapter describes the methods used to 
systematically collect this data. A custom-designed online survey was created to 
conduct a quantitative cross-sectional analysis of how MPs practice and utilize 
FDA-approved innovative techniques in the academic vs. community setting and 
rural vs. urban geographic locations. This provided the framework to develop a 
predictive model assessing possible barriers at the individual (MPs) and 
organizational (RO clinic) level, based on the previously discussed constructs. 
Details of the survey design, sampling procedures, power analysis, data analysis, 
threats to validity, and ethical procedures will be presented in the next chapter.  
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Chapter 3: Research Method 
Introduction 
As stated in Chapter 1, the purpose of this study was to investigate the 
accessibility of innovative services in RO in the United States and assess possible 
diffusion patterns using a quantitative cross-sectional survey. Surveying MPs to 
measure the diffusion of innovation in RO is in alignment with the ninth essential 
function of public health services to “evaluate effectiveness, accessibility, and 
quality of personal and population-based health services” (Centers for Disease 
Control and Prevention, 2017). As there are currently no indicators or instrument 
for measuring the accessibility of innovative services in RO in the United States, 
according to the literature review, this study quantified this issue and attempted to 
explain the barriers to adoption of innovative technologies in RO. In this chapter, 
the focus is on explaining the research design and rationale and the methodology 
used. The sampling and recruitment procedures are also discussed, as are the 
instrumentation and operationalization of constructs as they relate to the specific 
topic. Last, the threats to validity and ethical procedures are addressed. 
Research Design and Rationale 
This study aimed to measure the innovation score in RO in the United 
States. Innovation score is the dependent variable. For the purposes of this study, 
innovation score is defined as the sum of innovation indicators on product, 
technology, and organizational innovation. Product and technological innovation 
were measured as the ratio of the number of innovative techniques available or 
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purchased by a department divided by the number of the innovative techniques 
used clinically, weighed by partial implementation factors. Organizational 
innovation was measured as the weighted average of innovations used to 
reorganize procedures, work responsibilities, and decision-making. 
Independent variables in this study included variables at both the 
organizational and individual level. At the organizational level, independent 
variables included university affiliation and urbanicity. At the personal level, 
independent variables included gender, age, education, attendance of residency, 
certification status, interpersonal channels, leadership structure, group size, 
opinion leadership, appreciation, and motivation.  
The research design selected to investigate the possible connections 
between the dependent and independent variables was a quantitative cross-
sectional survey. Survey research is typically used for exploration, explanation, or 
description and involves the collection of descriptive, behavioral, and attitudinal 
data (Burkholder, 2015). In this study, survey research was used for explanatory 
purposes by collecting descriptive and behavioral data. Innovation score is not 
directly measured by any organization or vendor; thus, the only way to measure it 
was to ask MP responders to describe how they use innovations in their work and 
design a custom survey. Even if there were existing data on organizational 
characteristics and innovation implementation, individual level characteristics 
would not have been included. It was, therefore, necessary to reach out to 
individual MPs and collect self-reported data. 
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The survey was conducted exclusively online. This type of design is 
predominant in studies by health professionals, especially doctoral students 
(Rudestam & Newton, 2014). Web survey research has been shown to have lower 
costs, shorter length of time for field research, more flexible questionnaire design, 
higher percentage of questions answered completely and accurately, higher ability 
to administer complex instruments, shorter date processing time, lower error due 
to manual data entry, faster survey deployment, and a larger amount of available 
para-data (Dykema, Jones, Piché, & Stevenson, 2013). Potential disadvantages of 
Web survey designs include required access to Internet and email, the requirement 
of high computer literacy, increased likelihood of incomplete and erroneous 
contact information, lower response rates, slightly lower demographic 
representativeness, and decreased ability to administer incentives effectively 
(Dykema et al., 2013). For the purposes of this study, a web survey was selected 
because email communication is extensively used by and the preferred method of 
communication of MPs (American Association of Physicists in Medicine, 2017). 
Coincidentally, the use of a web survey aligned with the time and resource 
limitations of the study. 
Methodology 
Population 
In 2018, the AAPM directory listed approximately 7,500 members in total, 
and approximately 5,500 members are listed as active in the United States (not 
student, retired, associate, or corporate members) (American Association of 
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Physicists in Medicine, 2018). Seventy-seven percent of the membership reported 
being active in RO (American Association of Physicists in Medicine, 2018); thus, 
there were about 4,200 eligible MPs. Unofficial surveys typically garner an 
approximate 5-10% response rate and official surveys an approximate 30-35% 
response rate. (American Association of Physicists in Medicine, 2017) 
Considering this response rate and the estimated number of AAPM members, 
approximately 200 responses were expected for this survey.  
Sampling and Sampling Procedures 
Primary data was collected for this study using total population 
convenience sampling because the population is finite and a list was readily 
available. The MedPhysUSA listserv and AAPM Blackboard were used to recruit 
participants. The MedPhysUSA listserv is used extensively among MPs for 
survey dissemination, exchange of ideas, and general discussion. The listserv is 
hosted by Wayne University and had over 4,000 members at the time of study. 
Users must subscribe, and there are volunteer moderators. Forum policies were 
followed; no official permission was needed to post. The AAPM Blackboard is 
hosted by the AAPM and is open to all members for exchange of ideas and 
general discussion. No special permission was needed to post the survey. The 
survey was also posted on LinkedIn. LinkedIn retains data on user activity, as 
described in its privacy policy (“Privacy Policy, LinkedIn,” n.d.). All users agree 
to this policy as a condition of using the platform. The survey was designed using 
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an online survey research platform called SurveyMonkey (SurveyMonkey, 2019). 
The invitation post included brief description of the study and a link to the survey.  
Based on the expected participant number, a 5% chance of a Type I error 
and a 20% chance of a Type II error was reasonable. Statistical power of 80% was 
a reasonable initial goal as well. The typical four-to-one weighting was a good 
starting point for this study, and it will be further assessed after data collection. If 
the preliminary analysis reveals disproportional response rates between the 
categories of interest, these numbers may need to be altered. Type II errors, which 
encompass not detecting an effect that is actually there, or a false negative 
(Salazar, Crosby, & DiClemente, 2015), posed more significant social 
implications than Type I errors in this study. Not detecting an underperformance 
in community and rural RO centers might have led to a lack of supplemental 
efforts from AAPM to boost their utilization of new techniques and continuing 
population inequalities. Effect sizes are unknown since innovation in the United 
States has not been previously measured. Small to medium effect size of 0.2 were 
assumed. Based on these assumptions, G-Power (Faul, Erdfelder, Lang, & 
Buchner, 2007) calculated that approximately 200 responses were needed.  
Procedures for Recruitment, Participation, and Data Collection 
Participants were contacted passively by using the forums mentioned 
above. The invitation contained a brief description, incentive information, and a 
link to participate. Two reminders were sent approximately 10 days apart. The 
survey remained open for a total of thirty days. When participants opened the 
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link, they were taken to the introductory study page, where they were asked to 
consent to participate in the study. The survey contained a total of 70 questions 
and took approximately 5-10 minutes to complete (SurveyMonkey, 2018). 
Participants were asked multiple demographic and practice information as 
described in other sections. Participants were asked to enter an email address if 
they wish to receive a $10 Amazon gift card as an incentive to participate. This is 
a reasonable amount, as MP’s salaries start at $140,000 (American Association of 
Physicists in Medicine, 2018). The incentive was used to encourage participation. 
Dykema et al. (2013) analyzed the use of web surveys in clinicians and other 
healthcare providers and concluded that to achieve good response rate, incentives 
are needed to improve participation rates. Participants will exit the study after 
they complete the survey. No follow-up procedures are applicable.  
Instrumentation and Operationalization of Constructs 
Studies attempting to define and measure innovation in RO rely on custom 
survey design, as there is no centralized reporting mechanism. This was described 
in Chapter 2 as discussed by M. Jacobs et al. (2015) and Jacobs et al. (2016). This 
survey is an extension of the work done by these groups, who validated their 
innovation indicators using the Delphi method. Briefly, this Dutch group used 
consensus guidelines among RO chairpersons to define innovation in RO and 
used semi-structured interviews across 15 RO centers. 
Reliability and validity. Reliability was measured using inter-item 
reliability and split-half method. Chronbach’s alpha of 0.7 or higher was be used 
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to assess sufficient evidence of internal reliability (Salazar, Crosby, & 
DiClemente, 2015). Face validity and content validity were demonstrated by an 
expert panel. The expert panel was used to assess clarity of wording, applicability 
of answers, etc. Five MPs who fit the eligibility criteria were contacted in 
November 2018 and asked to review the survey and identify any ambiguity in the 
wording of the questions. Each expert panel participant was contacted via email 
and sent a preliminary version of the survey. Feedback was requested in writing 
within a week. Comments were received during a two-week period. Comment 
examples included the anonymity of the survey, stratification techniques, and 
length of the consent form. Additionally, comments were requested from the 
AAPM Technology Assessment office and received within 2 weeks in January 
2019. Four blinded field experts reviewed the survey and provided feedback on 
the structure and levels of measurement. All comments were used to improve the 
survey questions before deploying the study to the target population and enhance 
the study’s validity, as discussed in subsequent sections. Construct validity was 
demonstrated using principal component analysis (PCA) after data collection. 
Operationalization of Constructs. The dependent variable in this study is 
innovation score, which is defined as the sum of innovation indicators on product, 
technology, and organizational innovation. Product and technological innovation 
were measured as the ratio of the number of innovative techniques available or 
purchased by a department divided by the number of the innovative techniques 
used clinically, weighed by partial implementation factors. Organizational 
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innovation was measured as the weighted average of innovations used to re-
organize procedures, work responsibilities, and decision making. This is a 
continuous variable. For example, assume that there are ten indicators for product, 
technology, and organizational innovation and one of the responders has five 
available for use in their clinic. Out of those five, they use the first two all the 
time (100%), the third one most of the time (75%) and the last two half of the 
time (50%). The innovation score for this respondent will be 
(5/10)*[(100+100+75+50+50)/5] = 0.5*0.75 = 0.375. 
The independent variables are described in detail in Table 1. University 
affiliation was measured as a binary yes or no. Zip code text entry was converted 
to categorical using the RUCA continuum (USDA, 2013), explained in Appendix 
C. Gender was binary male or female. Age was measured as a continuous variable 
and was recoded into categorical. Education was measured as Master’s, Doctoral 
or other. Residency status was measured as a categorical variable, (yes, no, no 
didn’t need). ABR status was measured as yes, yes/other, or no. Interpersonal 
channels were measured as a continuous variable, using the number of meetings 
attended. Organizational structure was be measured as a categorical variable as 
physicist, physician, administrator. Group characteristics were measured as a 
categorical variable based on the size of the group. Opinion leadership was 
measured as a binary variable as yes or no. Appreciation was measured as a 
continuous variable. Motivation was measured as a continuous variable. Barriers 












Continuous 1, 2 3 
Q1: university affiliation University affiliation Binary 1a 
Q2: location Zip code Categorical 1b 
Q3-57 Barriers Continuous 3 
Q58: gender Gender Categorical 2 
Q59: Age Age Continuous 2 
Q60: degree Degree Binary 2 
Q61: residency Residency Categorical 2 
Q62: ABR status ABR status Categorical 2 
Q63: meeting attendance Interpersonal channels Continuous 2 
Q64: reporting organizational structure Categorical  2 
Q65: # of physicists Group characteristics Categorical 2 
Q66: volunteering Opinion leadership Categorical 2 
Q67: appreciation Appreciation Continuous 2 
Q68: motivation Motivation Continuous 2 
Q69: final thoughts Free text - - 
Q70: gift card Free text - - 
 
Data Analysis Plan 
After completing data collection, SPSS version 25 was used for statistical 
analysis. Data were screened for duplicates. Missing entries were reviewed for 
randomness, and data were removed pairwise when applicable. The RQs and 
hypotheses were as follows: 
RQ 1: What are the differences in accessibility to innovation in RO based on 
location and type of practice in the United States? 
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RQ 2: What are the statistically significant factors (demographics, practice details, 
context-specific psychological antecedents) that predict the accessibility to 
innovation in the RO clinic? 
RQ 3: What are the statistically significant barriers that MPs practicing in RO in 
the United States face in implementing innovations?  
Hypothesis 1a 
H1a0: There is no statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
H1a1: There is a statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
Dependent variable: innovation score (continuous). 
Independent variable: university affiliation (categorical, two levels: has 
university affiliation, does not have university affiliation). 
Hypothesis 1b 
H1b0: There is no statistically significant difference in the accessibility to 
innovation in RO between metropolitan and non-metropolitan hospitals. 
H1b1: There is a statistically significant difference in accessibility to 
innovation in RO between metropolitan and non-metropolitan hospitals. 
Dependent variable: innovation score (continuous). 






H20: There are no statistically significant factors predicting innovation 
score. 
H21: There are statistically significant factors predicting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: reporting structure, size of physics group, age, 
gender, DABR status, residency status, meeting attendance, education 
level, leadership,(categorical) appreciation, and motivation (continuous). 
Hypothesis 3 
H30: There are no statistically significant barriers affecting innovation 
score. 
H31: There are statistically significant barriers affecting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: barriers (continuous). 
Analysis plan. For RQ 1 the purpose is to compare groups, thus t-test and 
ANOVA were used  (Frankfort-Nachmias & Leon-Guerrero, 2015). T-test was 
used to compare innovation score for type of hospital variable and ANOVA was 
used to compare innovation between the RUCA urbanicity continuum. The t and 
F values and p-value were reported, along with means and standard deviations for 
all groups. Alternative non-parametric tests, such as the Mann-Whitney U and 
Kruskal-Wallis H tests, would have been selected if the dataset was found to have 
a significant deviation from normality. If homogeneity of variance was met, 
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Tukey's honestly significant difference (HSD) post hoc test was used to assess 
which specific groups differed. If the data did not meet the homogeneity of 
variances assumption, the Games Howell post hoc test would have been 
considered. 
For research question 2, multiple linear regression was initially planned to 
be used if the assumptions of linearity were met. The dependent variable was 
innovation score. This is a continuous variable. Independent variables in the 
model were respondents’ age, gender, education level, ABR status, residency 
status, interpersonal channels, appreciation level, motivation level, opinion 
leadership, practice organizational structure, and group characteristics. Alternative 
non-parametric tests were selected because the data did not meet normality 
criteria. To do so, the dependent variable (innovation score) was recoded to be 
binary categorical (below median, above median) and binomial logistic regression 
was used instead. 
For research question 3, correlation testing was used. The dependent 
variable was innovation utilization score. The independent variables are the 
individual barriers (lack of evidence, complexity, lack of time or staffing, lack of 
training or support, lack of interest, lack of interoperability, and lack of 
reimbursement. Pearson’s correlation was selected if the relationship between the 
dependent and independent variable is linear. Spearman correlation was selected 
if the data did not meet normality criteria. 
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Threats to Validity 
Threats to External Validity 
This study will reach the entire MPs population in the United States, thus 
threats to external validity due to sampling are limited (Cresswell, 2018). There 
is, however, the problem of volunteer bias, as participants who volunteer to be in 
a study about innovation may inherently be more innovative. The respondents 
may not be representative of the general population in regards to innovation 
practice or other characteristics. Additionally, there is inherent generalization 
across constructs on how the constructs apply to MPs specifically. For example, 
opinion leadership as a construct will be measured using volunteering in the 
AAPM. While participation in professional association leadership is a measure of 
opinion leadership in other disciplines (B. L. Jacobs et al., 2017), there is an 
inherent assumption that this connection transfers to MPs as well. This 
generalization across constructs may lead to extraneous or confounding variables 
in MPs. 
Threats to Internal Validity 
Extraneous effects may pose a threat to the internal validity of this study, 
as there may be excluded extraneous variables that were elusive during the 
literature review. This threat was minimized by the use of an expert panel who 
reviewed the survey before implementation. Additionally, there may be personal 
biases, which should be minimal due to the quantitative nature of the study. 
Participant reactivity may also be present in the study, as participants may 
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respond as being more innovative than they really are, suspecting that this is the 
desired behavior. This may affect the measurement of the dependent variable This 
is unlikely to have significant effects on an online professional survey, as this is 
most often observed in laboratory settings. These possible effects will be 
minimized as much as possible with the use of the appropriate multivariable 
analysis (Frankfort-Nachmias & Leon-Guerrero, 2015). 
Ethical Procedures 
Ethical considerations for the participants. Research participants have a 
moral obligation to answer truthfully. There are many surveys performed through 
the AAPM, including salary surveys for workforce forecasting, and 
confidentiality is not really a concern among members. The participant obligation 
will be emphasized at the beginning of the study, where the study's scope and 
rationale will be explained, in addition to the time commitment expected by the 
participants. Participants will be asked to acknowledge the expectations of their 
participation. This acknowledgment will serve as consent and as a “contract” 
between the participant and the researcher (Rudestam & Newton, 2014). 
Participants who are not MPs practicing in RO in the United States, yet 
participated for various reasons, would have violated the ethics of the consent. 
Various methods were used to positively reinforce truthful answers. Using 
a continuous, dependent-response scale (0-100 values) instead of a discrete, 
Likert-type scale for partial implementation is expected to have participants 
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answer more truthfully, versus a yes or no answer that may not be indicative of 
how exactly they are using these techniques. 
Ethical considerations for the researcher. The survey poses minimal 
risk to the participants, as the questions do not fall into the “traditional” sensitive 
information areas. Information can be perceived as sensitive when it involves 
cultural taboos, the threat of disclosure, or social desirability. What information is 
too private, or taboo, is extremely subjective and highly dependent on the culture 
(Epstein, Santo, & Guillemin, 2015). Participants were asked questions about how 
they perform their daily work duties, and none of the questions is of sensitive 
nature. The survey questions can, however, be seen as a surrogate to professional 
performance, and thus affect the respondent’s view of performance and self-
worth. Additionally, some of the questions will be about feelings of appreciation 
in the workplace. This may affect participants, as they typically may not have to 
think about something like that (Rudestam & Newton, 2014). This effect may be 
positive or negative, depending on the person and the situation. Possibility feeling 
uncomfortable was thus included in the study consent. 
Concerns over privacy will be handled using the anonymity features of the 
survey provider. The custom link will be provided along with the introductory 
text for the email. Email addresses will not be tracked. Additionally, concerns 
over Internet Protocol address (IP) tracking will be addressed by turning the 
feature off in the survey provider.  
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Institutional approval to conduct research. The Walden University 
Institutional Review Board (IRB) approved this study on April 24, 2019 (approval 
number 04-24-19-0603259, expiring April 23rd, 2020). 
Summary 
In this chapter, a detailed discussion of the research design and rationale 
as a total population convenience sampling cross-sectional survey was presented. 
The methodology, population, sampling procedures, instrumentation, and 
operationalization of constructs, data analysis plan were discussed. Possible 





Chapter 4: Results 
Introduction 
The purpose of this research study was to examine the diffusion of 
innovation in RO in the United States. To assess diffusion, a variety of statistical 
tests was used to compare innovation score with organizational and personal 
characteristics. A summary of the results is presented in this chapter. The 
following RQs were answered: 
RQ 1: What are the differences in accessibility to innovation in RO based on 
location and type of practice in the United States? 
RQ 2: What are the statistically significant factors (demographics, practice details, 
context-specific psychological antecedents) that predict the accessibility to 
innovation in the RO clinic? 
RQ 3: What are the statistically significant barriers that MPs practicing in RO in 
the United States face in implementing innovations?  
Data Collection 
The survey was posted on Saturday, April 27, 2019. The invitation is 
listed in Appendix B. During the first two weeks of the survey, 136 responses 
were collected. The first reminder was sent on Saturday, May 11, 2019, and the 
last reminder was sent on Wednesday, May 22, 2019. The survey closed on 
Saturday, June 1, 2019, at 11:50 pm. At the survey closure, 265 responses were 
collected. Twenty-five responses contained no answers at all. Thus, the final 
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sample size was 240. Incomplete data entries were excluded pairwise when 
applicable. The analysis was conducted using SPSS 25.  
Descriptive Statistics 
Independent variables were recoded as needed, taking into account the 
number of responses received. ZIP codes entered in the survey were converted to 
county, and the Rural-Urban Continuum Codes (Appendix C) were used to 
categorize locations as metropolitan and nonmetropolitan (USDA, 2013), as 
shown in Table 2. Most responses were received from metropolitan areas. 
University affiliation is also listed in Table 2; the sample contained approximately 
equal responses between university and non university facilities. Sample 
demographics for gender, education and age are shown in Table 3. Descriptive 
statistics for respondent appreciation and motivation are shown in Table 4. 
Sample professional characteristics for residency, DABR status, number of 
meetings in the past 10 years, reporting, number of physicists and volunteering 
are shown in Table 5. Principal component analysis was found to not a suitable 
test, as the overall Kaiser-Meyer-Olkin measure ranged from 0.588 to 0.634 





MPs Characteristics for RO center University Affiliation and Urbanicity 
Characteristic N f % 
University Affiliation 240   
Yes  111 46.3 
No  129 53.8 
Urbanicity 220   
RUCA Cat 1  138 62.7 
RUCA Cat 2  50 22.7 
RUCA Cat 3  17 7.7 
RUCA Cat 4  4 1.8 
RUCA Cat 5  4 1.8 
RUCA Cat 6  4 1.8 
RUCA Cat 7  3 1.4 
Urbanicity Binary 1 220   
RUCA Cat 1  138 62.7 
RUCA Cat 2-9  82 37.3 
Urbanicity Binary 2 220   
RUCA Categories 1-3  205 93.2 





MPs Demographics for RO  
Characteristic N f % 
Gender 188   
Male  155 82.4 
Female  33 17.6 
Education 190   
Master’s  118 62.1 
Doctoral  72 37.9 
Age distribution 183   
<  =  30  23 12.6 
31-40  70 38.3 
41-50  36 19.7 
51-60  30 16.4 
> 60  24 13.1 
 
Table 4 
Descriptive Statistics for RO Appreciation and Motivation in MPs 
 N M SD 
Appreciation 190 69.16 26.728 





MPs Professional Characteristics  
Characteristic N f % 
Residency 185   
Yes  77 41.6
No  108 58.4
DABR status 188   
DABR  150 79.8
not DABR/other  38 20.2
Number of meetings in the past 10 years 179   
0-5  104 58.1
6-9  42 23.5
> =  10  33 18.4
Reporting 189   
Another physicist  114 60.3
Physician  22 11.6
Administrator  37 19.6
VP/CEO  16 8.5 
Number of physicists 191   
1-3   98 51.3
≥ 4  93 48.7
Volunteer 185   
Yes  72 38.9





Dependent variable coding. The dependent variable, innovation score, 
was measured using 20 unique indicators in five categories: patient positioning, 
patient treatment, treatment planning, quality assurance, and workflow, as shown 
in Appendix D. Participants answers were entered using a slider with scale 0-100. 
For values entered as 0 or 1 on the slider, it was assumed that the respondents 
meant to not move the slider at all and that the type of innovation was not 
available. For values entered as 2 to 100 on the sliding scale, it was assumed that 
the respondents had the technology available to them. This categorized each 
respondent as having or not having the innovation. The innovation indicators were 
summed to calculate the innovation score for each category and the total 
innovation score for each respondent. This provided a measure for the diffusion of 
available innovative techniques and will be subsequently referred to as innovation 
score. The distribution is shown in Figure 1, and it appears to be normally 
distributed. 
Further, the exact number on the scale of individual responses was used to 
assess how respondents actually used the innovations available to them. This will 
be subsequently referred to as innovation utilization score, and it is distinctly 
different from the previously defined innovation score. A similar method 
described for innovation score was used for the innovation utilization score. The 
mean of the responses in each of the indicators in each category was used to 
calculate the innovation utilization score in each category separately. The 
innovation utilization score was calculated by adding the innovation utilization 
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score in the five categories. The distribution is shown in Figure 2, and it appears 
to be normally distributed.  
The Shapiro-Wilk test for normality was performed for innovation score 
and innovation utilization score, using university affiliation and urbanicity as 
factors. The results of the Shapiro-Wilk test were not statistically significant for 
the innovation score (p = 0.611) and for the innovation utilization score (p = 
0.699). Thus, the data were normally distributed. The Q-Q plots were also normal. 
The 20 parameters used to measure innovation were assessed for the 
reliability of the construct. The scale had a high level of internal consistency, as 
determined by a Cronbach's alpha of 0.963. 
 




Figure 2. Distribution of RO innovation utilization score. 
Study Results 
Research Question 1 Results 
Research Question (RQ) 1: What are the differences in accessibility to innovation 
in RO based on location and type of practice in the United States? 
H1a0: There is no statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
H1a1: There is a statistically significant difference in accessibility to 
innovation in RO between university and non-university hospitals. 
Dependent variable: innovation score (continuous). 
Independent variable: university affiliation (categorical, two levels: has 
university affiliation, does not have university affiliation). 
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Results for Hypothesis 1a. An independent t-test was performed to 
determine if there were differences in innovation score between university and 
non-university centers for the total innovation score and for the innovation 
utilization score. There were no outliers in the data, as assessed by inspection of a 
boxplot. There was homogeneity of variances, as assessed by Levene’s test for 
equality of variances for both the total innovation score (p = 0.689) and the 
innovation utilization score (p = 0.129).  
The mean innovation score difference for centers with university 
affiliation (M = 13.19, SD = 4.76) is higher than the mean innovation score for 
centers without a university affiliation (M = 11.55, SD = 4.63), a statistically 
significant difference MD = 1.65, 95% CI[0.38,2.917], t(211) = 2.56, p = 0.011, d 
= 0.351. Additionally, the patient treatment innovation score for university centers 
(M = 3.04, SD = 1.43) is higher than the patient treatment innovation score for 
non-university centers (M = 2.64, SD = 1.34), a statistically significant difference 
MD = 0.39, 95% CI[0.021,0.76], t(217) = 2.083, p = 0.038, d = 0.282; the 
workflow innovation score for university centers (M = 2.96, SD = 1.51) is higher 
than the workflow innovation score for non-university centers (M = 2.50, SD = 
1.55), a statistically significant difference MD = 0.46, 95% CI[0.05,0.86], t(217) = 
2.217, p = 0.028, d = 0.188. Results are presented in Tables 6 and 7. Cohen’s d 








N M SD SEM 
Patient Positioning 
Yes 106 2.217 1.087 .106 
No 113 2.018 1.035 .097 
Patient Treatment 
Yes 106 3.038 1.434 .139 
No 113 2.646 1.349 .127 
Treatment 
Planning 
Yes 106 2.292 1.441 .139 
No 113 2.115 1.361 .128 
Quality Assurance 
Yes 106 2.311 1.539 .149 
No 113 1.956 1.454 .137 
Workflow 
Yes 106 2.962 1.505 .146 
No 113 2.504 1.548 .146 
Total 
Yes 103 13.194 4.757 .469 










for Equality of 
Variances 
t-test for Equality of Means 





Equal variances assumed 1.009 .316 1.390 217 .166 .199 .144 -.083 .485 
Equal variances not 
assumed 
  1.388 214 .167 .199 .144 -.084 .482 
Patient 
Treatment 
Equal variances assumed .003 .953 2.083 217 .038 .392 .188 .021 .762 
Equal variances not 
assumed 
  2.079 211 .039 .392 .188 .0203 .763 
Treatment 
Planning 
Equal variances assumed 1.510 .221 .937 217 .350 .177 .189 -.196 .550 
Equal variances not 
assumed 
  .935 214 .351 .177 .189 -.196 .551 
Quality 
Assurance 
Equal variances assumed 1.966 .162 1.758 217 .080 .356 .202 -.043 .754 
Equal variances not 
assumed 
  1.755 214 .081 .356 .203 -.044 .755 
Workflow 
Equal variances assumed 1.152 .284 2.217 217 .028 .458 .207 .051 .865 
Equal variances not 
assumed 
  2.219 217 .028 .458 .206 .051 .864 
Total 
Equal variances assumed .160 .689 2.562 211 .011 1.649 .644 .379 2.917 
Equal variances not 
assumed 




The mean innovation utilization score for centers with university 
affiliation (M = 59.39, SD = 17.74) is similar to the mean innovation utilization 
score for centers without a university affiliation (M = 60.62, SD = 15.97). The 
innovation utilization score difference is not statistically significant based on 
university affiliation. However, for the five categories measured, the mean 
workflow innovation utilization score for centers with university affiliation (M = 
54.05, SD = 22.85) is higher than the mean workflow innovation utilization score 
for centers without a university affiliation (M = 46.95, SD = 19.92), a statistically 
significant difference MD = 7.09, 95% CI[0.78,13.39], t(178) = 2.217, p = 0.028, 
d = 0.330. Results are presented in Tables 8 and 9. Cohen’s d was calculated 
manually. Thus, the null hypothesis H1a,0 is rejected, and the alternate H1a,1 is 
accepted. 
Table 8 





N M SD SEM 
Patient 
Positioning 
Yes 90 60.985 25.089 2.645 
No 98 63.908 23.681 2.392 
Patient Treatment 
Yes 96 76.195 24.681 2.519 
No 102 76.769 25.208 2.496 
Treatment 
Planning 
Yes 91 48.092 26.226 2.749 
No 95 51.637 24.973 2.562 
Quality 
Assurance 
Yes 85 56.022 28.503 3.092 
No 86 61.565 23.893 2.576 
Workflow 
Yes 90 54.045 22.859 2.410 
No 90 46.959 19.921 2.099 
Total 
Yes 103 59.393 17.749 1.749 




Independent Samples T-Test for RO center Innovation Utilization Score and 
University Affiliation 
Category 
Levene's Test for 
Equality of 
Variances 
t-test for Equality of Means 







.172 .679 -.822 186 .412 -2.923 3.557 -9.941 4.095 
Equal variances 
not assumed 





.588 .444 -.162 196 .872 -.575 3.546 -7.573 6.423 
Equal variances 
not assumed 





.269 .605 -.944 184 .346 -3.545 3.754 -10.952 3.861 
Equal variances 
not assumed 





3.361 .069 -1.38 169 .170 -5.544 4.020 -13.481 2.392 
Equal variances 
not assumed 




2.542 .113 2.217 178 .028 7.086 3.196 .771 13.39 
Equal variances 
not assumed 




2.317 .129 -.531 211 .596 -1.227 2.311 -5.782 3.33 
Equal variances 
not assumed 







H1b0: There is no statistically significant difference in the accessibility to 
innovation in RO between metropolitan and non-metropolitan hospitals. 
H1b1: There is a statistically significant difference in accessibility to 
innovation in RO between metropolitan and non-metropolitan hospitals. 
Dependent variable: innovation score (continuous) 
Independent variable: urbanicity (categorical, metropolitan, and non-
metropolitan) 
Results for Hypothesis 1b. An independent t-test was performed to 
determine if there were differences in innovation score between metropolitan and 
non-metropolitan centers for the total innovation score and for the innovation 
utilization score. There were no outliers in the data, as assessed by inspection of a 
boxplot. There was homogeneity of variances, as assessed by Levene’s test for 
equality of variances for both the total innovation score (p = 0.478) and the 
innovation utilization score (p = 0.855). It is noted that total innovation score was 
assessed using binary RUCA categorization 1 and 2-9, while innovation 
utilization score was assessed using binary RUCA categorization 1-3 and 4-9. 
Results are presented in Tables 10 to 13.  
The mean innovation score for metropolitan centers (M = 12.94, SD = 
4.65) is similar to the mean innovation score for non-metropolitan centers (M = 
11.69, SD = 4.37). The innovation score difference is not statistically significant 
based on metropolitan or non-metropolitan status, even though d = 0.275. 
79 
  
However, for the five categories measured, the mean patient positioning 
innovation score for metropolitan centers (M = 2.21, SD = 1.02) is higher than the 
mean patient positioning innovation score for non-metropolitan centers (M = 
1.89, SD = 1.12), a statistically significant difference MD = 0.31, 95% 
CI[0.011,0.612], t(203) = 2.043, p = 0.042, d = 0.293. Additionally, the mean 
patient treatment innovation score for metropolitan centers (M = 3.08, SD = 1.36) 
is higher than the mean patient treatment innovation score for non-metropolitan 
centers (M = 2.47, SD = 1.33), a statistically significant difference MD = 0.62, 
95% CI[0.23,1.00], t(203) = 3.145, p = 0.002, d = 0.457. Results are presented in 
Tables 10 and 11. Cohen’s d was calculated manually. 
Table 10 
Group Statistics for RO center Innovation Score and Urbanicity 
Category UrbanicityBinary1 N M SD SEM 
Patient Positioning 
RUCA 1 130 2.208 1.025 .090 
RUCA 2-9 75 1.893 1.122 .130 
Patient Treatment 
RUCA 1 130 3.085 1.364 .120 
RUCA 2-9 75 2.467 1.340 .155 
Treatment Planning 
RUCA 1 130 2.354 1.375 .121 
RUCA 2-9 75 2.000 1.356 .157 
Quality Assurance 
RUCA 1 130 2.169 1.536 .135 
RUCA 2-9 75 2.160 1.395 .161 
Workflow 
RUCA 1 130 2.823 1.553 .136 
RUCA 2-9 75 2.707 1.431 .165 
Total 
RUCA 1 127 12.937 4.653 .413 






Independent Samples T-Test for RO center Innovation Score and Urbanicity 
Category 
Levene's Test for Equality of 
Variances t-test for Equality of Means 







1.090 .298 2.043 203 .042 .314 .154 .011 .618
Equal variances not 
assumed 
  





.176 .675 3.145 203 .002 .618 .196 .230 1.005
Equal variances not 
assumed 
  





.536 .465 1.784 203 .076 .354 .198 -.037 .745
Equal variances not 
assumed 
  





1.997 .159 .043 203 .966 .009 .216 -.416 .434
Equal variances not 
assumed 
  




3.040 .083 .532 203 .595 .116 .219 -.315 .548
Equal variances not 
assumed 
  




.505 .478 1.849 197 .066 1.243 .672 -.083 2.568
Equal variances not 
assumed 
  







The mean innovation utilization score for metropolitan centers (M = 
60.73, SD = 16.67) is similar to the mean innovation utilization score for non-
metropolitan centers (M = 55.41, SD = 15.38). The total innovation utilization 
score difference is not statistically significant based on metropolitan or non-
metropolitan status, even though d = 0.331. However, for the five categories 
measured, the mean patient positioning innovation utilization score for 
metropolitan centers (M = 63.96, SD = 23.78) is higher than the mean patient 
positioning innovation utilization score for non-metropolitan centers (M = 47.73, 
SD = 29.28), a statistically significant difference MD = 16.22, 95% 
CI[0.73,31.72], t(173) = 2.067, p = 0.04, d = 0.608. Results are presented in 
Tables 12 and 13. Cohen’s d was calculated manually. Thus, the null hypothesis 






Group Statistics for RO center Innovation Utilization Score and Urbanicity 
Category UrbanicityBinary2 N M SD SEM 
Patient Positioning 
RUCA 1-3 165 63.958 23.784 1.852 
RUCA 4-9 10 47.733 29.287 9.262 
Patient Treatment 
RUCA 1-3 175 78.023 23.493 1.776 
RUCA 4-9 11 72.897 25.561 7.707 
Treatment 
Planning 
RUCA 1-3 166 50.171 25.228 1.958 
RUCA 4-9 11 43.606 28.433 8.573 
Quality Assurance 
RUCA 1-3 152 57.803 25.949 2.105 
RUCA 4-9 11 69.955 25.739 7.761 
Workflow 
RUCA 1-3 164 50.896 21.894 1.710 
RUCA 4-9 8 40.042 18.073 6.390 
Total 
RUCA 1-3 186 60.726 16.673 1.223 













t-test for Equality of Means 





Equal variances assumed 1.463 .228 2.067 173 .040 16.22 7.849 .732 31.72 
Equal variances not 
assumed 
  1.718 10 .117 16.22 9.445 -4.90 37.35 
Patient 
Treatment 
Equal variances assumed .067 .795 .698 184 .486 5.13 7.339 -9.35 19.61 
Equal variances not 
assumed 
  .648 11 .530 5.13 7.909 -12.3 22.52 
Treatment 
Planning 
Equal variances assumed .221 .639 .829 175 .408 6.56 7.915 -9.06 22.19 
Equal variances not 
assumed 
  .747 11 .471 6.56 8.794 -12.8 25.91 
Quality 
Assurance 
Equal variances assumed .043 .836 -1.50 161 .135 -12.15 8.098 -28.1 3.84 
Equal variances not 
assumed 
  -1.51 12 .158 -12.15 8.041 -29.8 5.45 
Workflow 
Equal variances assumed .214 .644 1.379 170 .170 10.86 7.875 -4.69 26.40 
Equal variances not 
assumed 
  1.641 8 .139 10.86 6.614 -4.38 26.09 
Total 
Equal variances assumed .034 .855 1.115 197 .266 5.310 4.762 -4.1 14.70 
Equal variances not 
assumed 




Research Question 2 Results 
Research Question (RQ) 2: What are the statistically significant factors 
(demographics, practice details, context-specific psychological 
antecedents) that predict the accessibility to innovation in the RO clinic? 
H20: There are no statistically significant factors predicting innovation 
score. 
H21: There are statistically significant factors predicting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: reporting structure, size of physics group, age, 
gender, DABR status, residency status, meeting attendance, education 
level, leadership, (categorical) appreciation, and motivation (continuous). 
Bivariate analysis for appreciation, motivation, and number of 
meetings. The Shapiro-Wilk test for normality was performed for innovation 
score and innovation utilization score using appreciation, motivation, and number 
of meetings as factors (continuous variables). The results of the Shapiro-Wilk test 
were statistically significant for all three parameters (p < 0.001). Thus, the data 
are not normally distributed. The Q-Q plots were also not normal. Spearman 
correlation was used to perform bivariate analysis for appreciation and 
motivation. There was a positive correlation between innovation utilization and 
participant appreciation (rs = 0.224, p = 0.002) and motivation (rs = 0.215, p = 
0.003). Both correlations are of small to medium effect size class, according to 
Cohen’s criteria (Ellis, 2010). There was a small negative correlation between 
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innovation utilization and the number of meetings attended (rs = -0.186, p = 
0.013). Since this result is unexpected, the relationship with total innovation score 
was also investigated. Results were not statistically significant (rs = 0.067, p = 
0.371). Thus, the number of meetings will not be included in the final regression 
model. 
Bivariate analysis for gender, opinion leadership, education, and 
residency status. The Shapiro-Wilk test for normality was performed for 
innovation score and innovation utilization score using gender, opinion 
leadership, education, and residency as factors (binary variables). The results of 
the Shapiro-Wilk test were not statistically significant for gender (p = 0.433), 
opinion leadership (p = 0.172), education (p = 0.922), and residency (p = 0.981). 
Thus, the data are normally distributed. The Q-Q plots were also normal. An 
independent sample t-test was performed for gender, opinion leadership, 
education, and residency. Results were not statistically significant for gender (p = 
0.828), opinion leadership (p = 0.921), and residency (p  = 0.402). Results were 
statistically significant for education. The mean innovation utilization score for 
Master’s degree (M = 61.42, SD = 16.11) is higher than the mean innovation 
utilization score for Doctoral degree (M = 56.37, SD = 17.22), a statistically 
significant difference MD = 5.06, 95% CI[0.18,9.94], t(188) = 2.046, p = 0.042, d 
= 0.278. 
Bivariate analysis for age, DABR status, number of meetings, 
reporting structure, and number of physicists. The Shapiro-Wilk test for 
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normality was performed for innovation score and innovation utilization score 
using age, DABR status, number of meetings, reporting structure, and number of 
physicists as factors (categorical variables). The results of the Shapiro-Wilk test 
were not statistically significant for meetings (p = 0.425), age (p = 0.768), DABR 
status (p = 0.573), reporting structure (p = 0.739), and the number of physicists (p 
= 0.431). There was no statistically significant effect of age (p = 0.38), DABR 
status (p = 0.10), reporting status (p = 0.06), and the number of physicists in 
practice (p = 0.57).  
Binary logistic regression. Three parameters were found to be 
statistically significant in affecting innovation implementation: degree, 
motivation, and appreciation. Since the two latter are non-linear, a binomial 
logistic regression was performed. The dependent variable, innovation utilization, 
was recoded to binary (1 = below median, 2 = above median, Mdn = 60.03). 
Linearity of the continuous variables with respect to the logit of the dependent 
variable was assessed using the Box-Tidwell procedure. The interaction term was 
not statistically significant for motivation (p = 0.587), and for appreciation (p = 
0.338), thus these two independent variables are linearly related to the logit of the 
dependent variable. No corrections were applied. Results of the binary logistic 





Binary Logistic Regression Omnibus Tests of Model Coefficients 
 χ2 df p 
Step 1 Step 10.861 3 .013 
Block 10.861 3 .013 
Model 10.861 3 .013 
 
Table 15 
Binary Logistic Regression Model Summary 
Step -2 Log likelihood Cox & Snell R Square Nagelkerke R Square 
1 250.720a .056 .075 




Binary Logistic Regression Hosmer and Lemeshow Test 
Step χ2 df p 
1 6.187 8 .626 
 
Table 17 
Binary Logistic Regression Classification Table 
Observed Predicted 
 




















   60.8 




Binary Logistic Regression Results and Variables in the Equation for Innovation 
Utilization (outcome variable) 






Education -.600 .315 3.620 1 .057 .549 .296 1.018 
Appreciation .013 .008 2.385 1 .122 1.013 .997 1.030 
Motivation .001 .009 .005 1 .944 1.001 .983 1.019 
Constant -.821 .560 2.151 1 .142 .440   
a. Variable(s) entered on step 1: Education, Appreciation, Motivation. 
There were no cases with studentized residuals greater than 2.0. The 
Hosmer and Lemeshow Test was not statistically significant (p = 0.626), thereby 
suggesting a model fit. The logistic regression model was statistically significant, 
χ2(3) = 10.861, p = 0.013. The model explained 7.5% (Nagelkerke R2) of the 
variance in innovation utilization and correctly classified 60.8% of cases. 
Sensitivity was 55.6%, specificity was 65.7%, positive predictive value was 
59.5%, and the negative predictive value was 38.1%. None of the predictor 
variables was statistically significant. Thus, the null hypothesis H2,0 is accepted, 
and the alternate H2,1 is rejected. 
Research Question 3 Results 
RQ 3: What are the statistically significant barriers that MPs practicing in RO in 
the United States face in implementing innovations?  




H31: There are statistically significant barriers affecting innovation score. 
Dependent variable: innovation score (continuous). 
Independent variables: barriers (continuous). 
Seven measured barriers across five categories and in total were assessed 
for normality. The results of the Shapiro-Wilk test were mixed, with some values 
being statistically significant, and some not being statistically significant (data not 
shown). Thus, the data are assumed to not be normally distributed as a group. The 
Q-Q plots were also not normal. The seven parameters used to assess barriers 
were assessed for the reliability of the construct. The scale had a high level of 
internal consistency, as determined by a Cronbach's alpha of 0.882. Spearman 
correlation was used to perform bivariate analysis across each category and in 
total. Spearman’s rho results are presented in Tables 19 to 25. 
There are statistically significant barriers in patient treatment, treatment 
planning, quality assurance, workflow, and innovation utilization total. Lack of 
interest is a small statistically significant barrier in patient treatment innovation 
utilization (rs = 0.199, p<0.05). Lack of inter-operability is a small statistically 
significant barrier in workflow innovation utilization (rs = 0.218, p<0.05). Lack of 
time and staffing is a small statistically significant barrier in quality assurance 
innovation utilization (rs = -0.178, p<0.05). The negative correlation sign is noted 
and will be further discussed in Chapter 5. There are multiple small statistically 
significant barriers in treatment planning, such as lack of evidence (rs = 0.203, 
p<0.05), complexity (rs = 0.175, p<0.05), lack of time and staffing (rs = 0.237, 
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p<0.01), lack of inter-operability (rs = 0.203, p<0.05), and lack of reimbursement 
(rs = 0.269, p<0.01). There are multiple small statistically significant barriers in 
total innovation utilization, such as lack of evidence (rs = 0.161, p<0.05), lack of 
interest (rs = 0.264, p<0.01), lack of inter-operability (rs = 0.214, p<0.01), and 
lack of reimbursement (rs = 0.176, p<0.05). All statistically significant 
correlations in the study were of small to medium effect size class, according to 
Cohen’s definition (Ellis, 2010). Thus, the null hypothesis H3,0 is rejected, and the 


















rs 1.000 -.010 -.084 -.014 -.008 .005 .040 .068 
P . .915 .331 .870 .929 .949 .644 .459 
N 188 118 135 149 131 144 138 121 
Evidence rs -.010 1.000 .475** .199* .441** .279** .271** .272** 
P .915 . .000 .032 .000 .003 .005 .007 
N 118 127 115 116 109 111 107 96 
Complexity rs -.084 .475** 1.000 .430** .553** .265** .352** .161 
P .331 .000 . .000 .000 .003 .000 .093 
N 135 115 146 134 119 125 123 110 
Time/ 
Staffing 
rs -.014 .199* .430** 1.000 .535** .387** .208* .218* 
P .870 .032 .000 . .000 .000 .018 .018 
N 149 116 134 165 136 142 130 117 
Training/ 
Support 
rs -.008 .441** .553** .535** 1.000 .527** .404** .299** 
P .929 .000 .000 .000 . .000 .000 .002 
N 131 109 119 136 142 128 117 105 
Interest rs .005 .279** .265** .387** .527** 1.000 .432** .357** 
P .949 .003 .003 .000 .000 . .000 .000 
N 144 111 125 142 128 162 131 119 
Inter 
Operability 
rs .040 .271** .352** .208* .404** .432** 1.000 .469** 
P .644 .005 .000 .018 .000 .000 . .000 
N 138 107 123 130 117 131 150 111 
Reimbursement rs .068 .272** .161 .218* .299** .357** .469** 1.000 
P .459 .007 .093 .018 .002 .000 .000  
N 121 96 110 117 105 119 111 134 
*. Correlation is significant at the 0.05 level (2-tailed). 




















rs 1.000 .187 -.009 .032 .054 .199* .170 .177
P . .066 .927 .721 .595 .030 .086 .085
N 198 97 118 129 101 119 103 96
Evidence rs .187 1.000 .560** .452** .547** .426** .413** .385**
P .066 . .000 .000 .000 .000 .000 .001
N 97 102 91 91 82 86 82 75
Complexity rs -.009 .560** 1.000 .534** .664** .270** .471** .402**
P .927 .000 . .000 .000 .007 .000 .000
N 118 91 122 112 95 99 93 86
Time/ 
Staffing 
rs .032 .452** .534** 1.000 .558** .367** .280** .364**
P .721 .000 .000 . .000 .000 .005 .000
N 129 91 112 132 100 106 98 90
Training/ 
Support 
rs .054 .547** .664** .558** 1.000 .455** .545** .407**
P .595 .000 .000 .000 . .000 .000 .000
N 101 82 95 100 105 92 86 80
Interest rs .199* .426** .270** .367** .455** 1.000 .474** .519**
P .030 .000 .007 .000 .000 . .000 .000
N 119 86 99 106 92 122 95 85
Inter 
Operability 
rs .170 .413** .471** .280** .545** .474** 1.000 .513**
P .086 .000 .000 .005 .000 .000 . .000
N 103 82 93 98 86 95 107 83
Reimbursement rs .177 .385** .402** .364** .407** .519** .513** 1.000
P .085 .001 .000 .000 .000 .000 .000 .
N 96 75 86 90 80 85 83 100
*. Correlation is significant at the 0.05 level (2-tailed). 



















rs 1.000 .203* .175* .092 .237** .129 .203* .269**
P . .030 .042 .255 .005 .140 .030 .004
N 186 115 135 155 136 133 114 111
Evidence rs .203* 1.000 .361** .308** .456** .344** .529** .357**
P .030 . .000 .001 .000 .000 .000 .001
N 115 119 107 112 102 105 91 91
Complexity rs .175* .361** 1.000 .470** .495** .392** .517** .532**
P .042 .000 . .000 .000 .000 .000 .000
N 135 107 143 138 126 120 101 98
Time/ 
Staffing 
rs .092 .308** .470** 1.000 .580** .426** .295** .477**
P .255 .001 .000 . .000 .000 .002 .000
N 155 112 138 163 135 131 108 108
Training/ 
Support 
rs .237** .456** .495** .580** 1.000 .399** .574** .376**
P .005 .000 .000 .000 . .000 .000 .000
N 136 102 126 135 144 120 105 100
Interest rs .129 .344** .392** .426** .399** 1.000 .477** .543**
P .140 .000 .000 .000 .000 . .000 .000
N 133 105 120 131 120 145 105 101
Inter 
Operability 
rs .203* .529** .517** .295** .574** .477** 1.000 .522**
P .030 .000 .000 .002 .000 .000 . .000
N 114 91 101 108 105 105 119 90
Reimbursement rs .269** .357** .532** .477** .376** .543** .522** 1.000
P .004 .001 .000 .000 .000 .000 .000 .
N 111 91 98 108 100 101 90 119
*. Correlation is significant at the 0.05 level (2-tailed). 



















rs 1.000 .124 .037 -.178* -.083 -.168 -.105 -.027
P . .225 .707 .036 .388 .059 .264 .800
N 171 97 108 140 110 128 116 91
Evidence rs .124 1.000 .503** .383** .470** .377** .466** .338**
P .225 . .000 .000 .000 .000 .000 .002
N 97 108 90 99 87 96 92 81
Complexity rs .037 .503** 1.000 .531** .582** .355** .442** .312**
P .707 .000 . .000 .000 .000 .000 .005
N 108 90 117 113 101 99 97 78
Time/ 
Staffing 
rs -.178* .383** .531** 1.000 .651** .538** .490** .222*
p .036 .000 .000 . .000 .000 .000 .038
N 140 99 113 155 115 130 114 88
Training/ 
Support 
rs -.083 .470** .582** .651** 1.000 .626** .573** .234*
p .388 .000 .000 .000 . .000 .000 .042
N 110 87 101 115 120 105 95 76
Interest rs -.168 .377** .355** .538** .626** 1.000 .507** .482**
p .059 .000 .000 .000 .000 . .000 .000
N 128 96 99 130 105 147 107 89
Inter 
Operability 
rs -.105 .466** .442** .490** .573** .507** 1.000 .416**
p .264 .000 .000 .000 .000 .000 . .000
N 116 92 97 114 95 107 125 80
Reimbursement rs -.027 .338** .312** .222* .234* .482** .416** 1.000
p .800 .002 .005 .038 .042 .000 .000 .
N 91 81 78 88 76 89 80 102
*. Correlation is significant at the 0.05 level (2-tailed). 



















rs 1.000 .111 .118 -.051 -.050 -.034 .210* -.034
p . .303 .209 .525 .581 .679 .033 .746
N 180 88 115 155 125 149 103 91
Evidence rs .111 1.000 .420** .295** .411** .546** .543** .387**
p .303 . .000 .006 .000 .000 .000 .001
N 88 91 87 86 85 82 80 75
Complexity rs .118 .420** 1.000 .475** .642** .278** .539** .309**
p .209 .000 . .000 .000 .003 .000 .004
N 115 87 120 115 103 109 92 84
Time/ 
Staffing 
rs -.051 .295** .475** 1.000 .625** .497** .202* .407**
p .525 .006 .000 . .000 .000 .042 .000
N 155 86 115 161 122 146 102 92
Training/ 
Support 
rs -.050 .411** .642** .625** 1.000 .486** .437** .319**
p .581 .000 .000 .000 . .000 .000 .003
N 125 85 103 122 130 119 98 83
Interest rs -.034 .546** .278** .497** .486** 1.000 .278** .428**
p .679 .000 .003 .000 .000 . .005 .000
N 149 82 109 146 119 156 101 89
Inter 
Operability 
rs .210* .543** .539** .202* .437** .278** 1.000 .352**
p .033 .000 .000 .042 .000 .005 . .002
N 103 80 92 102 98 101 106 74
Reimbursement rs -.034 .387** .309** .407** .319** .428** .352** 1.000
p .746 .001 .004 .000 .003 .000 .002 .
N 91 75 84 92 83 89 74 95
*. Correlation is significant at the 0.05 level (2-tailed). 



















rs 1.000 .161* .085 .111 .027 .264** .214** .176*
p . .038 .254 .120 .722 .000 .005 .025
N 213 166 183 199 180 195 174 162
Evidence rs .161* 1.000 .458** .353** .517** .391** .495** .445**
p .038 . .000 .000 .000 .000 .000 .000
N 166 166 159 165 155 161 152 145
Complexity rs .085 .458** 1.000 .424** .596** .252** .478** .372**
p .254 .000 . .000 .000 .001 .000 .000
N 183 159 183 183 169 177 164 150
Time/ 
Staffing 
rs .111 .353** .424** 1.000 .609** .500** .393** .394**
p .120 .000 .000 . .000 .000 .000 .000
N 199 165 183 199 178 191 171 159
Training/ 
Support 
rs .027 .517** .596** .609** 1.000 .469** .505** .355**
p .722 .000 .000 .000 . .000 .000 .000
N 180 155 169 178 180 173 160 149
Interest rs .264** .391** .252** .500** .469** 1.000 .384** .435**
p .000 .000 .001 .000 .000 . .000 .000
N 195 161 177 191 173 195 165 157
Inter 
Operability 
rs .214** .495** .478** .393** .505** .384** 1.000 .569**
p .005 .000 .000 .000 .000 .000 . .000
N 174 152 164 171 160 165 174 147
Reimbursement rs .176* .445** .372** .394** .355** .435** .569** 1.000
p .025 .000 .000 .000 .000 .000 .000 .
N 162 145 150 159 149 157 147 162
*. Correlation is significant at the 0.05 level (2-tailed). 




Table 25  








QA Workflow Total 
Evidence   0.203*   0.161* 
Complexity   0.175*    




Training/Support       
Interest  0.199*    0.264**
Interoperability   0.203*  0.218* 0.214**
Reimbursement   0.269**   0.176* 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 Summary 
The three research questions posed were answered. The null hypotheses 
H1a, H1b, and H3were rejected, and null hypothesis H2 was accepted. There are 
statistically significant differences in the accessibility of innovative services based 
on hospital university affiliation and urbanicity, with more innovative services 
being available to patients treated in urban, university hospitals. There are 
statistically significant predicting factors that affect the accessibility of innovative 
services, with MP appreciation and motivation having a weak predictive 
relationship with increased accessibility of innovative services, albeit the model is 
not statistically significant. There are statistically significant barriers MPs face in 
providing access to innovative services to patients. In Chapter 5 there will be a 
98 
  
detailed discussion on the implications of these results and recommendations for 
future research.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
The purpose of this study was to investigate the accessibility of innovative 
services in RO in the United States and assess possible diffusion patterns using an 
online survey of MPs practicing in the United States. The dependent variable was 
innovation score. Independent variables were geographic location; practice details 
(university affiliation, reporting structure, and size of physics group); 
demographics (age, gender, DABR status, residency status, meeting attendance, 
and education level); and context-specific psychological antecedents (motivation, 
appreciation, and leadership).  
There were statistically significant differences in the accessibility of 
innovative services based on hospital university affiliation and urbanicity, with 
more innovative services being available to patients treated in urban, university 
hospitals. Also, there are statistically significant predicting factors that affect the 
accessibility of innovative services, with MP appreciation and motivation having 
a weak predictive relationship with increased accessibility of innovative services. 
Finally, there were statistically significant barriers in patient treatment, treatment 
planning, quality assurance, and workflow. Findings indicate that MPs face 
challenges in providing access to innovative services to patients. In this chapter, 
the results are discussed in context, the study limitations, and recommendations 





Known proportions of organizational and personal characteristics were 
retrieved from the most recent salary survey for RO MPs (American Association 
of Physicists in Medicine, 2018). This report lists primary employment settings as 
private or community hospital, government hospital, medical school or university 
hospital, college or university, government hospital, medical physics service 
group, physician group, industrial or commercial firm, and cancer center. It is 
unclear if some categories are correlated--for example, there can be a cancer 
center with a university affiliation. This self-identification can be subjective; this 
is the reason this classification was not selected for this study. The report is 
useful, however, in providing some baseline descriptive statistics. Based on this 
report, 17% of master’s-level MPs work in centers with university affiliation, and 
83% of PhD physicists work in centers with university affiliation. On average, 
50% of MPs are employed by centers with a university affiliation, 26% of MPs 
are women, 55% hold a master’s degree, 89% are certified by the ABR, and 28% 
graduated from a residency. 
In analyzing the sample descriptive statistics and comparison to known 
proportions, it is concluded that there are similarities in percentages of university 
affiliation, type of degree, and DABR status, but not for gender and residency. 
The respondent gender ratio was higher for male and higher for residency 
graduates. There are no publicly available proportions for age distribution, but the 
respondent age distribution appears to be skewed towards younger respondents, 
101 
  
which is in alignment with the higher response rate for residency graduates. No 
exact known proportions are known for urbanicity, meetings attended, reporting 
structure, number of physicists, volunteer status, appreciation or motivation. It is 
thus concluded that the sample was overall representative of the population. 
Open-Ended Feedback 
The study included a free-text comment section at the end of the survey. 
Many of the comments revolved around the cost of innovation, which was 
expected. An unexpected common thread, however, was concerns about 
maintaining safety. MP participants were highly concerned that using innovations 
and changing the status quo might be inconsistent with maintaining patient safety. 
This finding was unexpected because all innovations in question are FDA-
approved and commercially available. The pathway to deteriorating safety would 
be possible only through poor implementation. This circles back to workflow 
innovation. A conclusion is that MPs do not feel innovation improves patient 
safety and/or they do not know how to safely implement innovations in the clinic. 
Interpretation of the Findings 
University Affiliation and Innovation 
In Research Question 1a it was demonstrated that centers with a university 
affiliation have a higher mean innovation score than centers without a university 
affiliation (MD = 1.65, 95% CI [0.38,2.917], t(211) = 2.56, p = 0.011, d = 0.351). 
As discussed in the literature review in Chapter 2, there are many outcome 
differences between academic and nonacademic centers. While the difference in 
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innovation score is likely not the only factor contributing to outcome differences, 
it is a factor that needs to be incorporated in future models. The results of this 
study are in congruence with similar studies performed in the United States (see 
Pfister et al., 2015). It is interesting to note that the two categories with 
statistically significant results are patient treatment and workflow. The parameters 
affecting the patient treatment innovation score (stereotactic body radiosurgery, 
stereotactic cranial radiosurgery, robotic radiosurgery, intraoperative radiation 
therapy, and flattening free beams) are techniques that are only available in newer 
accelerators, which are in their majority multimillion-dollar investments. 
In Research Question 1a it was also demonstrated that centers with 
university affiliation have a higher mean workflow utilization score than centers 
without a university affiliation (MD = 7.09, 95% CI [0.78,13.39], t(178) = 2.217, 
p = 0.028, d = 0.330). This finding is interesting because organizational 
innovation has not previously been studied in RO in the United States, as typically 
publications focus on technological differences (see Chen, 2014)). The results of 
this study are in congruence with the published results from the Netherlands (M. 
Jacobs, 2017). Improving workflows can be a low-risk, high-yield opportunity for 
many centers lacking the funds for large investments. A curriculum with core and 
adjunct tools for MPs is currently under development through the Medical 
Physics Leadership Academy Working Group (J. Johnson, personal 
communication, MPLAW Retreat, May 2019). The lack of statistically significant 
differences in other categories is a positive finding for the industry, as it implies 
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that once centers break through the barrier of purchasing innovative technologies, 
there are no major differences in utilizing them.  
Urbanicity and Innovation 
In Research Question 1b it was demonstrated that urban centers have a 
higher innovation scores in patient positioning (MD = 0.31, 95% CI 
[0.011,0.612], t(203) = 2.043, p = 0.042, d = 0.293) and patient treatment (MD = 
0.62, 95% CI [0.23,1.00], t(203) = 3.145, p = 0.002, d = 0.457). Thus, the results 
of this study are in congruence with similar studies performed in the United States 
(Charlton et al., 2015). The quantitative assessment did not reveal large 
differences for total innovation, which was an unexpected result. This is possibly 
due either to the low power of the study or the RUCA classification that was used 
in this study; greater granularity may be necessary. The results were plotted on a 
map of the United States for qualitative analysis, as shown in Figure 3. The 
population was superimposed with innovation score (darker green, higher 
population). Additionally, all RO the centers that are currently operational in the 
United States are superimposed as black squares (IAEA DIRAC database, 2018). 
The heatmap represents centers that are more innovative (red) versus less 
innovative (blue). The most innovative centers are in close proximity and in areas 
with high population density. Conversely, areas with low population density have 
the lowest innovation score. This qualitative assessment does support the claim 
that urban centers provide more innovative treatments, despite the absence of 











Figure 3. Map of the United States with innovation utilization score. Hawaii is 
not to scale. No data were received for Alaska. Map layers include population 
density as shades of green and RO centers as squares.  
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While differences in patient treatment are relatively easy to explain due to 
purchasing decision and competition in urban centers, the differences in patient 
positioning may not be so obvious. Patient positioning is typically decided at the 
time of simulation and is the primary responsibility of the radiation therapists. 
Historically there is great variation in MPs involvement in patient positioning and 
setup reproducibility, with some MPs being very involved, and some MPs being 
absent in the simulation process (Clements et al., 2018). The introduction of 
mandatory MP residencies is closing this gap. The increase in hypo-fractionated 
treatments has also changed this dynamic, as discussed in the 2014 AAPM 
summer school on “safely and accurately delivering high precision, hypo-
fractionated treatments” and AAPM reports (Halvorsen et al., 2017). However, 
there may be discordance of information flowing to the American Society of 
Radiologic Technologists. Another possible explanation is that in urban centers, 
patients “shop around” for their treatment, with higher socioeconomic status 
patients often requesting or demanding certain types of treatment (Martin, 
Thomas, Harden, & Burnet, 2015; Roubou & Alexopoulou, 2015). Frequent 
examples from personal experience include prone breast treatments or large full-
body immobilization.  
Education and Innovation 
In Research Question 2, it was demonstrated that the mean innovation 
utilization score for MPs with a Master’s degree is higher than the mean 
innovation utilization score for Doctoral degree (MD = 5.06, 95% CI[0.18,9.94], 
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t(188) = 2.046, p = 0.042, d = 0.278). Out of the 118 respondents with a Master’s 
degree, 41.5% were employed by a center with a university affiliation, and 58.5% 
of respondents were employed by a center without a university affiliation. Out of 
the 72 respondents with a Doctoral degree, 58.3% were employed by a center 
with a university affiliation, and 41.7% of respondents were employed by a center 
without a university affiliation. The survey did not ask participants the topic of 
their doctoral degree. It is possible that MPs with doctoral degrees in medical 
physics are employed in university hospitals with higher innovation scores, while 
MPs with doctoral degrees in other fields are employed in non-university 
hospitals with lower innovation scores. This discrepancy does not exist for 
Master’s degree, as the Master’s degree must be in Medical Physics to qualify for 
certification. Even though the results are statistically significant, education is 
likely to have a more complicated relationship with innovation. It is possible that 
Masters level physicists are more motivated and competitive, but this requires 
further study. This may partially explain the poor model fit in Research Question 
2. 
Appreciation and Motivation in Innovation 
In Research Question 2, it was demonstrated that there is a small positive 
correlation between innovation utilization and participant appreciation (rs = 0.224, 
p = 0.002) and motivation (rs = 0.215, p = 0.003). Even though the correlations 
were small, the results are in congruence with prior published studies in general 
and in the health care setting (Wisdom et al., 2014). It is important to note that 
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this is the first time these parameters have been measured for MPs, and results are 
in agreement with studies done on other health care professionals (Strömgren, 
Eriksson, Bergman, & Dellve, 2016). Appreciation and motivation are often 
considered “soft skills” that may be shunned by MPs in leadership positions 
(Gutierrez, Halvorsen, & Rong, 2017). This common misconception is declining 
since the introduction of the Medical Physics Leadership Academy and the 2016 
summer school (J. Johnson, personal communication, July 14, 2019). The results 
of this study will serve to strengthen the base of evidence supporting intra-
personal skills and clinical performance. 
Barriers to Innovation Utilization 
Four categories were found to have statistically significant barriers: patient 
treatment, treatment planning, quality assurance, and workflow. Statistically 
significant barriers were also detected for innovation utilization total. There were 
no statistically significant barriers detected for patient positioning, possibly due to 
lack of statistical power. Training and support was not a statistically significant 
barrier for any of the categories investigated. This result is in agreement with the 
AAPM TG 100 report listing training as the least effective tool of a quality 
management program (Huq et al., 2016).  
In the patient treatment category, lack of interest is a statistically 
significant but with small effect size barrier in patient treatment innovation 
utilization (rs = 0.199, p<0.05). It is noted that the patient treatment category 
involved very advanced techniques, see Appendix D for details. This lack of 
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interest can be further explained in the context of university affiliation and 
urbanicity. Interestingly, university centers in metropolitan areas had even higher 
correlation coefficients for lack of interest in patient treatment innovation 
utilization (results not shown). This finding may be an indicator of complacency 
due to market domination (Martin et al., 2015; Roubou & Alexopoulou, 2015). 
In the treatment planning category, five out of the seven barriers were 
found to be statistically significant: lack of evidence (rs = 0.203, p<0.05), 
complexity (rs = 0.175, p<0.05), lack of time and staffing (rs = 0.237, p<0.01), 
lack of inter-operability (rs = 0.203, p<0.05), and lack of reimbursement (rs = 
0.269, p<0.01). This is an alarming result; even though the coefficients are small, 
there are multiple barriers. The highest coefficient, reimbursement, is the obvious 
first choice for discussion. The treatment planning Current Procedural 
Terminology (CPT) codes have been steadily decreasing, stagnant or bundled in 
(“Reimbursement-American Society for Radiation Oncology (ASTRO)”, n.d.). In 
health care in general, it has been well demonstrated that financial incentives 
increase innovation utilization (Darzi & Parston, 2013). This conlusion is 
congruent with the second-highest coefficient, lack of time and staffing resources. 
In the absence of reimbursement, faced with low staffing support, the barrier to 
innovation is significant. Facilities with mixed vendor products may face high 
inter-operability issues, which are unfortunately unsolvable at the clinic level. 
There is a growing number of publications on evidence for treatment planning 
innovations and their effect on productivity and outcomes (Gintz et al., 2016; 
109 
  
Wang, Dong, Liu, & Xing, 2017), however, the results of this study show that 
critical mass has not yet been reached. The complexity of treatment planning  
innovations continues to be discouraging to users. These results may be of 
particular interest to treatment planning vendors and to AAPM workgroups 
writing recommendations for treatment planning.  
In the quality assurance category, lack of time and staffing is a small 
negative statistically significant barrier in quality assurance innovation utilization 
(rs = -0.178, p<0.05). The negative relationship means that lower staffing levels 
are correlated to higher innovation in quality assurance. This result can be 
explained in the context of daily clinical work. It is reasonable to assume that 
MPs have been forced into using innovations in quality assurance to compensate 
for reduced staffing levels. For example, the first category indicator, portal 
dosimetry, may take some initial time to set up, but the time gains for performing 
device-less quality assurance for every patient multiple times per week is a 
significant efficiency gain in the clinic. A similar concept applies to other 
indicators in the quality assurance category (Eckhause et al., 2015; Thompson et 
al., 2018). While it is positive that MPs are using quality assurance innovations, 
the instigating factor may be convenience. This is in contrast with treatment 
planning findings: when there is reduced staffing or time for treatment planning, 
MPs do not use the innovations to gain time (for example with automatic planning 
or automatic contouring) but instead do not use these innovations. This may be 
due to the significant resource investment needed to create some of these 
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downstream benefits, and the involvement of other groups, such as dosimetrists 
and radiation oncologists, who may not be positive towards these innovations 
either (Georg & Thwaites, 2017). In contrast, physicists operate independently in 
tasks in the quality assurance category. 
In the workflow category, lack of inter-operability is a small statistically 
significant barrier in workflow innovation utilization (rs = 0.218, p < 0.05). In the 
context of workflow, inter-operability is not to be interpreted in a technical 
context, but more as the compatibility of heterogeneous business processes. In 
this frame of reference, MPs are encountering barriers in workflow innovations 
when the innovations are perceived to be incompatible with existing policies and 
procedures or standards of practice. This result is in agreement with prior results 
in the Netherlands (M. Jacobs et al., 2017). It is possible that MPs have so far 
been reluctant to get involved in process improvement and business development 
planning. As previously discussed, these avenues are now being explored by the 
AAPM and the Leadership Academy. 
In total innovation utilization, there are multiple small statistically 
significant barriers, such as lack of evidence (rs = 0.161, p < 0.05), lack of interest 
(rs = 0.264, p<0.01), lack of inter-operability (rs = 0.214, p < 0.01), and lack of 
reimbursement (rs = 0.176, p<0.05). The coefficients are small, yet statistically 
significant. MPs face non-supportive organizational cultures in their clinics. This 
is a key finding of this study. Clinics as organizational entities have selected to 
reject innovations and maintain status quo, possibly due to the incorrect 
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association of innovations as a compromise to safety, the cornerstone of modern 
RO. 
Limitations of the Study 
The presented study has limitations. Due to the study design, there was a 
possible selection bias. The study may not have reached some MPs, especially 
those who practice in rural areas. Since there are no known proportions of MPs 
per ZIP code, the effect of this limitation is impossible to calculate. Comparison 
with known proportions of university versus non-university centers showed a 
reasonable degree of agreement, which implies that selection bias was not a 
significant source of bias in this study. Another possible source of bias mentioned 
in Chapter 1, information bias, could also have influenced the results. 
Unfortunately, there is no way to assess the magnitude of this effect either. Both 
of selection bias and information bias are inherent to the study design.  
Additionally, as mentioned in Chapter 4, there was a high level of internal 
consistency, as determined by Cronbach's alpha of 0.963. This statistic in 
combination with the face and content validity of the expert panel review leads to 
the conclusion that the constructs have high reliability. However, there were many 
assumptions made in the operationalization of constructs. It is possible that not all 
predictive parameters were included in the model, or operationalized 
appropriately. This would partially explain the poor fit of the predictive model. 
Additionally, the operationalization of constructs may not be transferable outside 
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the United States, thus results should be applied with caution outside of the 
United States.  
Furthermore, there are statistical limitations. The effect sizes used to 
calculate a priori power were hypothetical and chosen conservatively. Post hoc 
analysis for university status reveals that based on the detected sample effect size, 
the power of the study was 0.72. This may be slightly smaller than the intended 
0.8, yet still within reason. Conversely, the power for the RUCA continuum 
ranged from 0.52 to 0.88, depending on the model selected. This is because of the 
selected RUCA continuum and the low response rates from areas closer to the 
rural end of the spectrum. It is uncertain if the effect sizes measured in this study 
are true population effect sizes or sample effect sizes, thus results should be 
interpreted with caution until effect sizes are confirmed by future studies.  
Lastly, this was a cross-sectional study, thus the study design does not 
allow the investigation of temporal relationships and possible causality between 
the dependent and independent variables.  Causal effects are typically 
demonstrated by experimental study designs (Salazar et al., 2015). However, the 
results are congruent with theoretical causal structures used in population health 
(Darzi & Parston, 2013). 
Recommendations 
It is recommended that this study can be repeated in the future under the 
aegis of the AAPM, possibly by a task group or workgroup. If so, the 
questionnaire or survey should be designed to limit selection and information 
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bias, the two biggest limitations of this study. This could be achieved by 
addressing the study to the department chair, manager, or chief physicist. 
Changing the unit of measurement to the RO department, instead of the individual 
MPs could also serve to minimize the aforementioned sources of bias. Even 
without AAPM support, the results of this study should be validated by other 
researchers. It would be particularly interesting to perform similar studies outside 
the United States, assess generalizability and compare effect sizes.  
Additionally, it is recommended that there is further theoretical 
exploration on appreciation and motivation in health care leadership theory. There 
is rich literature on emotional intelligence, organizational culture, and employee 
motivation, but the connection to appreciation is not obvious. Very little has been 
written about appreciation in the work environment. The Society for Human 
Resource Management, (2012) claims that even though 51% of supervisors claim 
they recognize good performance, only 17% of the same organization’s 
employees feel recognized. The term “appreciative leadership” is often used in 
popular management literature. Scholarly work does address appreciative 
behaviors relating to praise and recognition, using verbiages such as support, 
respect, constructive feedback, social reinforcement, and appreciation (Stocker, 
Jacobshagen, Krings, Pfister, & Semmer, 2014). A possible expansion to the path-
goal theory of leadership (House, 1996), as it applies to healthcare, may be 
necessary to fill this gap. 
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Another important aspect for further research is the transferability to 
Radiation Therapy Technologists and Radiation Oncologists. These professionals, 
along with MPs are in the front lines of daily clinical practice. The American 
Society for Radiologic Technologists (ASRT) would be an obvious choice for 
collaboration and dissemination of these findings. Similarly, collaborating with 
Radiation Oncologists and ASTRO would be the logical route to further the 
presented research and delve into qualitative and quantitative aspects of 
organizational culture. MPs do not practice in isolation. It is possible that a better 
predictive model could be derived using inter-team and intra-team dynamics 
(Reiter-Palmon, 2017). Removing the barriers to innovation utilization in the 
clinic must be a collaborative team effort. 
Implications 
Instrument Development and Benchmarking 
During the literature review stage of this study, there was an evident 
relationship between the ninth essential public health service to “evaluate 
effectiveness, accessibility, and quality of personal and population-based health 
services” and innovation accessibility in RO. There was no available data or an 
instrument to effectively measure innovation in RO. This gap in itself is a barrier 
to improving the equity of delivery of appropriate treatment to all cancer patients. 
The need for a metric of innovation utilization was previously an abstract concept 
discussed only in theory. This study has now delivered an instrument to quantify 
innovation in RO. This quantitative instrument, along with qualitative work done 
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by others, will be used to improve innovation utilization in RO. The data collected 
in this study can serve as a benchmark of the state of innovation today, with plans 
on how to improve it in the future. 
Social Change Implications 
Inequalities in health are parallel to inequalities in health care (Frenk, 
2013). To improve public health further in the 21st century, there needs to be an 
inclusion of factors outside of traditionally-defined health care (DeSalvo, 2017). 
Disparities in access to advanced care have an impact on cancer survival. This 
statement may be considered contradictory by some, but it is well supported by 
recent literature (Nardi et al., 2016; Pfister et al., 2015; Wolfson, Sun, Wyatt, 
Hurria, & Bhatia, 2015). There are is an abundance of differences between centers 
that may have a causal effect on improved cancer survival. Innovation is only one 
of these parameters. This study did not attempt to show causal effects, as this can 
only be demonstrated by clinical trials (B. L. Jacobs et al., 2017). What this study 
did demonstrate, however, is that there are indeed differences in innovation 
accessibility in RO in the United States. The connection between innovation and 
improved cancer survival has been made by many authors; innovation-based care 
models are under discussion in reimbursement health care reform (Alvarnas, 
Majkowski, & Levine, 2015; Nardi et al., 2016). Thus, using the results of this 
study to further how innovation is measured in RO in the United States, and 
assess how the measured barriers can be minimized is a positive social change. 
Public health is expanding beyond government agency programs to a broader 
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cross-sectoral practice (DeSalvo, 2017). RO as a community is in a position to 
further engage public health aspects that have a collective impact on population 
health. 
Conclusion 
In this study, innovation in RO in the United States was measured for the 
first time, through the development of a new survey instrument. Rural centers and 
centers with no academic affiliation are trailing behind in innovation 
implementation. Motivation and appreciation were shown to be statistically 
significant personal factors influencing innovation utilization, but no predictive 
model was possible. Barriers in RO innovation implementation were also 
assessed, with treatment planning showing the most statistically significant 
barriers. 
RO practitioners follow an ethos of “as low as reasonably achievable” 
every day, making every attempt possible to reduce dose to patients. We do this 
almost subconsciously, as it has been engrained in our training as common sense. 
Getting MPs to view embracing innovation as part of their culture will only be 
possible if innovation is not considered to be competing with safety. The 
complementary relationship between safety and innovation is being discussed in 
many other health care fields. If every MPs practiced using “as innovative as 
reasonably achievable” as their mantra, similar to “as low as reasonably 
achievable”, patients would benefit immensely. This is a worthy end goal to be 
striving towards. This study provides a small but promising step in this direction. 
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Although the exact number of lives saved or extended because of innovations in 
daily practices in RO may never be known, it is certainly worth it to try to make 
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Appendix A: Survey 
Diffusion of Innovation in Radiation Oncology Survey 
emailemailemailemail 
First, tell us a few things about the organization you practice in. 
1. Does the Radiation Oncology practice you are responding for has a university 
or university hospital affiliation? 
   Yes, there is a university or university hospital affiliation.  
   No, there is no university or university hospital affiliation. 
2.In what ZIP code is the practice located? (enter 5-digit ZIP code; for example, 
22314). Answers will be used strictly for geocoding purposes. 
Organization products and technologies used for patient positioning and 
monitoring 
Are any of the following products and technologies used in your department? 
If yes, to what degree are they used? Use the slider to respond. What 
barriers do you face for each category? 














What barriers do you face in the implementation of innovation on patient 
positioning and monitoring techniques? 
6.Lack of evidence and publications on the relative advantage of the 
innovation 
 












9.Lack of training and support 
 
 
10.Lack of interest from others, no supporting organizational culture 
 
 
11.Lack of inter-operability with existing technology and practices 
 
 




Are any of the following products and technologies used in your department? If 
yes, to what degree are they used? Use the slider to respond. What barriers do 
you face for each category? 
 
 








Category: Patient Treatment 
13.Stereotactic Body Radiosurgery 
 









16.Intra-Operative Radiation Therapy 
 
17.Flattening Filter Free beams 
 
What barriers do you face in the implementation of innovation on patient 
treatment techniques? 




19.Complexity of the innovation 
 
 










21.Lack of training and support 
 
 
22.Lack of interest from others, no supporting organizational culture 
 
 
23.Lack of inter-operability with existing technology and practices 
 
 




Are any of the following products and technologies used in your department? If 
yes, to what degree are they used? Use the slider to respond. What barriers do 
you face for each category? 
Category: Treatment planning 
25.Automatic/knowledge-based contouring 
 













What barriers do you face in the implementation of innovation on treatment 
planning? 















32.Lack of training and support 
 
 
33.Lack of interest from others, no supporting organizational culture 
 
 








Are any of the following products and technologies used in your department? If 
yes, to what degree are they used? Use the slider to respond. What barriers do 
you face for each category? 
 








Category: Quality Assurance 
36.Portal Dosimetry for linear accelerator QA 
 
37.QA trending and statistical process control 
 
38.Automated machine QA 
 
39.Automated plan checks 
 
What barriers do you face in the implementation of innovation on quality 
assurance? 










41.Complexity of the innovation 
 
 




43.Lack of training and support 
 
 
44.Lack of interest from others, no supporting organizational culture 
 
 
45.Lack of inter-operability with existing technology and practices 
 
 
46.Lack of reimbursement 
 
 
Organization products and technologies used for workflow                                                             









If yes, to what degree are they used? Use the slider to respond. What 
barriers do you face for each category? 
Category: Workflow 
47.Does your clinic participate in clinical trials 
 
48.Does your clinic develop new practices for organizing procedures (for 




49.Does your clinic develop new methods for organizing work responsibilities 
and decision making (for example new training systems etc) 
 
50.Does your clinic develop new methods of organizing external relationships 
with other organizations or public institutions (for example alliances for first 
use of an innovation, partnerships, outsourcing or sub- contracting innovations) 
 
 Sometimes  
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What barriers do you face in the implementation of innovation on workflow? 




52.Complexity of the innovation 
 
 




54.Lack of training and support 
 
 
55.Lack of interest from others, no supporting organizational culture 
 
 












57.Lack of reimbursement 
 
 
58.What is your gender? 
Male  
Female 
Other (please specify) 
59.Please enter your age 
60.What is the highest degree you have received? 
 Master’s degree 
  Doctoral degree 
   Other (please specify) 
61.Have you completed a Medical Physics Residency? 
 No, I began my practice before the residency mandate.  
 No, I was not accepted in one 
  Yes, I successfully completed a Medical Physics Residency 
62.Are you certified by the American Board of Radiology? 
 Yes, I am a diplomate of the American Board of Radiology  
 Not yet, I have only passed Part I 




 No, I do not hold any certification  
 No, but I hold a different certification 
63.How many national meetings have you attended in the past 10 years? Please 
enter a number. A full list of AAPM and ASTRO meetings is shown below. 
AAPM Annual 2009 in Anaheim, California  
AAPM Annual 2010 in Philadelphia, Philadelphia  
AAPM Annual 2011 in Vancouver, BC 
AAPM Annual 2012 in Charlotte, North Carolina  
AAPM Annual 2013 in Indianapolis, Indiana  
AAPM Annual 2014 in Austin, Texas 
AAPM Annual 2015 in Anaheim, California 
AAPM Annual 2016 in Washington, District of Columbia  
AAPM Annual 2017 in Denver, Colorado 
AAPM Annual 2018 in Nashville, Tennessee 
AAPM Spring Clinical 2009 in Virginia Beach, Virginia  
AAPM Spring Clinical 2010 in San Antonio, Texas 
AAPM Spring Clinical 2011 in Chattanooga, Tennessee  
AAPM Spring Clinical 2012 in Dallas, Texas 
AAPM Spring Clinical 2013 in Phoenix, Arizona  
AAPM Spring Clinical 2014 in Denver, Colorado  
AAPM Spring Clinical 2015 in Denver, Colorado  
AAPM Spring Clinical 2016 in Salt Lake City, UT 
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AAPM Spring Clinical 2017 in New Orleans, Louisiana  
AAPM Spring Clinical 2018 on Las Vegas, Nevada  
ASTRO Annual 2009 in Chicago, Illinois 
ASTRO Annual 2010 in San Diego, California  
ASTRO Annual 2011 in Miami, Florida 
ASTRO Annual 2012 in Boston, Massachusetts  
ASTRO Annual 2013 in Atlanta, Georgia 
ASTRO Annual 2014 in San Francisco, California 
ASTRO Annual 2015 in San Antonio, Texas ASTRO Annual 2016 in Boston, 
Massachusetts ASTRO Annual 2017 in San Diego, California ASTRO 
Annual 2018 in San Diego, California ASTRO Annual 2018 in San Antonio, 
Texas 
AAPM Spring Clinical Meeting 2019 in Orlando, Florida 
64.Who do you report to? 
 Another Physicist (e.g. Chief Physicist / Physics Director/ Physics 
Chair)  
   A Radiation Oncologist (e.g. Program Director / Department Chair) 
   An Administrator (e.g. Manager / Director)  
   A Vice President 




65.How many Physicists practice in the same location, including yourself? 
 I am the only one  
 2-3 
   3-5 
   5-10 
   >10 
   Don’t know 
66.Have you ever volunteered in AAPM committees or leadership? 
 Yes 
 No 
67.Do you feel appreciated at work? 
 
 
68.Do you feel motivated at work? 
 
 
69.Please share any final thoughts you may have on innovation in Radiation 
Oncology 
70.If you would like to receive a $10 Amazon gift card, please enter your email. 





Appendix B: Invitation Emails 
Invitation E-email Sent April 27, 2019 
Email Title: 
Take the Diffusion of Innovation in Radiation Oncology Survey and receive a $10 
Amazon gift card. 
Email Body: 
What innovative techniques are available in Radiation Oncology across the 
country and how much are they actually used in daily clinical work? Medical 
Physicists practicing in the United States are invited to participate in a 5-10 
minute research study to find diffusion patterns and explore barriers in using 
innovative techniques in Radiation Oncology. 
Please share this survey link with any Medical Physicists practicing in Radiation 
Therapy in the United States you may know. 
https://www.surveymonkey.com/r/DiffusionOfInnovationSurvey 
This study will remain open until 5/24/2019 11:59 pm EST. You will receive two 
additional reminders. If you choose to participate and enter your email at the end, 
you will receive a $10 Amazon gift card, or skip that step to remain completely 
anonymous. Anonymized aggregate data will be used to conduct a quantitative 
cross-sectional analysis to assess how innovation may vary depending on 
individual and organizational factors. 




First Reminder E-email Sent May 11, 2019 
Email title: 
First reminder: Take the Diffusion of Innovation in Radiation Oncology Survey 
and receive a $10 Amazon gift card. 
Email Body 
What innovative techniques are available in Radiation Therapy across the country 
and how much are they actually used in daily clinical work? Medical Physicists 
practicing in the United States are invited to participate in a 5-10 minute research 
study to find diffusion patterns and explore barriers in using innovative 
techniques in Radiation Oncology. 
Please share this survey link with any Medical Physicists practicing in Radiation 
Therapy in the United States you may know. 
https://www.surveymonkey.com/r/DiffusionOfInnovationSurvey 
This survey will remain open until 5/24/2019 11:59pm EST. You will receive one 
additional reminder. If you choose to participate and enter your email at the end, 
you will receive a $10 Amazon gift card, or skip that step to remain completely 
anonymous. Anonymized aggregate data will be used to conduct a quantitative 
cross-sectional analysis to assess how innovation may vary depending on 
individual and organizational factors. 





Final Reminder Email Sent May 22, 2019 
Email title: 
Second and final reminder: Take the Diffusion of Innovation in Radiation 
Oncology Survey and win a $10 Amazon gift card. 
Email Body: 
What innovative techniques are available in Radiation Therapy across the country 
and how much are they actually used in daily clinical work? Medical Physicists 
practicing in the United States are invited to participate in a 5-10 minute research 
study to find diffusion patterns and explore barriers in using innovative 
techniques in Radiation Oncology. 
Please share this survey link with any Medical Physicists practicing in Radiation 
Therapy you may know. 
https://www.surveymonkey.com/r/DiffusionOfInnovationSurvey 
This survey will remain open until 5/24/2019 11:59pm EST. This is the final 
reminder. If you choose to participate and enter your email at the end, you will 
receive a $10 Amazon gift card, or skip that step to remain completely 
anonymous. Anonymized aggregate data will be used to conduct a quantitative 
cross-sectional analysis to assess how innovation may vary depending on 
individual and organizational factors. 




Appendix C: 2013 Rural-Urban Continuum Codes 
 Code Description 
Metropolitan 
1 Counties in metro areas of 1 million population or more 
2 Counties in metro areas of 250,000 to 1 million population 




4 Urban population of 20,000 or more, adjacent to a metro area 
5 
Urban population of 20,000 or more, not adjacent to a metro 
area 
6 Urban population of 2,500 to 19,999, adjacent to a metro area 
7 
Urban population of 2,500 to 19,999, not adjacent to a metro 
area 
8 
Rural or less than 2,500 urban population, adjacent to a metro 
area 
9 






Appendix D: Indicators Used for Innovation Score Determination 
Category Indicator 
Patient positioning 




Stereotactic body radiosurgery 
Stereotactic cranial radiosurgery 
Robotic radiosurgery 
Intra-operative radiation therapy 
Flattening free beams 
Treatment planning 
Automatic contouring 












New external relations 
 
